<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phosphodiesterase 5 inhibitors for pulmonary hypertension - Barnes, H - 2019 | Cochrane Library</title> <meta content="Phosphodiesterase 5 inhibitors for pulmonary hypertension - Barnes, H - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012621.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phosphodiesterase 5 inhibitors for pulmonary hypertension - Barnes, H - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012621.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012621.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Phosphodiesterase 5 inhibitors for pulmonary hypertension" name="citation_title"/> <meta content="Hayley Barnes" name="citation_author"/> <meta content="The Alfred Hospital" name="citation_author_institution"/> <meta content="hayleynbarnes@gmail.com" name="citation_author_email"/> <meta content="Zoe Brown" name="citation_author"/> <meta content="St Vincent's Hospital" name="citation_author_institution"/> <meta content="Andrew Burns" name="citation_author"/> <meta content="St Vincent's Hospital" name="citation_author_institution"/> <meta content="Trevor Williams" name="citation_author"/> <meta content="The Alfred Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012621.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012621.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012621.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012621.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Endothelin Receptor Antagonists [therapeutic use]; Hypertension, Pulmonary [*drug therapy, etiology, mortality]; Numbers Needed To Treat; Phosphodiesterase 5 Inhibitors [adverse effects, *therapeutic use]; Placebos [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Walk Test" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012621.pub2&amp;doi=10.1002/14651858.CD012621.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="UDgTyLGV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012621\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012621\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","fr","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012621.pub2",title:"Phosphodiesterase 5 inhibitors for pulmonary hypertension",firstPublishedDate:"Jan 31, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012621.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012621.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012621.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012621.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012621.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012621.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012621.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012621.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012621.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012621.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8227 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012621.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0158"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-sec-0152"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/appendices#CD012621-sec-0163"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/table_n/CD012621StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/table_n/CD012621StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phosphodiesterase 5 inhibitors for pulmonary hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#CD012621-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hayley Barnes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#CD012621-cr-0003">Zoe Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#CD012621-cr-0004">Andrew Burns</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information#CD012621-cr-0005">Trevor Williams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information/en#CD012621-sec-0170">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012621.pub2">https://doi.org/10.1002/14651858.CD012621.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012621-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012621-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012621-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012621-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012621-abs-0001" lang="en"> <section id="CD012621-sec-0001"> <h3 class="title" id="CD012621-sec-0001">Background</h3> <p>Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right‐heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left‐heart disease (PH‐LHD); Group 3 comprises PH as a result of lung diseases or hypoxia, or both; Group 4 includes PH due to chronic thromboembolic occlusion of pulmonary vasculature (CTEPH), and Group 5 consists of cases of PH due to unclear and/or multifactorial mechanisms including haematological, systemic, or metabolic disorders. Phosphodiesterase type 5 (PDE5) inhibitors increase vasodilation and inhibit proliferation. </p> </section> <section id="CD012621-sec-0002"> <h3 class="title" id="CD012621-sec-0002">Objectives</h3> <p>To determine the efficacy of PDE5 inhibitors for pulmonary hypertension in adults and children. </p> </section> <section id="CD012621-sec-0003"> <h3 class="title" id="CD012621-sec-0003">Search methods</h3> <p>We performed searches of CENTRAL, MEDLINE, Embase, CINAHL, and Web of Science up to 26 September 2018. We handsearched review articles, clinical trial registries, and reference lists of retrieved articles. </p> </section> <section id="CD012621-sec-0004"> <h3 class="title" id="CD012621-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials that compared any PDE5 inhibitor versus placebo, or any other PAH disease‐specific therapies, for at least 12 weeks. We include separate analyses for each PH group. </p> </section> <section id="CD012621-sec-0005"> <h3 class="title" id="CD012621-sec-0005">Data collection and analysis</h3> <p>We imported studies identified by the search into a reference manager database. We retrieved the full‐text versions of relevant studies, and two review authors independently extracted data. Primary outcomes were: change in WHO functional class, six‐minute walk distance (6MWD), and mortality. Secondary outcomes were haemodynamic parameters, quality of life/health status, dyspnoea, clinical worsening (hospitalisation/intervention), and adverse events. When appropriate, we performed meta‐analyses and subgroup analyses by severity of lung function, connective tissue disease diagnosis, and radiological pattern of fibrosis. We assessed the evidence using the GRADE approach and created 'Summary of findings' tables. </p> </section> <section id="CD012621-sec-0006"> <h3 class="title" id="CD012621-sec-0006">Main results</h3> <p>We included 36 studies with 2999 participants (with pulmonary hypertension from all causes) in the final review. Trials were conducted for 14 weeks on average, with some as long as 12 months. Two trials specifically included children. </p> <p>Nineteen trials included group 1 PAH participants. PAH participants treated with PDE5 inhibitors were more likely to improve their WHO functional class (odds ratio (OR) 8.59, 95% confidence interval (CI) 3.95 to 18.72; 4 trials, 282 participants), to walk 48 metres further in 6MWD (95% CI 40 to 56; 8 trials, 880 participants), and were 22% less likely to die over a mean duration of 14 weeks (95% CI 0.07 to 0.68; 8 trials, 1119 participants) compared to placebo (high‐certainty evidence). The number needed to treat to prevent one additional death was 32 participants. There was an increased risk of adverse events with PDE5 inhibitors, especially headache (OR 1.97, 95% CI 1.33 to 2.92; 5 trials, 848 participants), gastrointestinal upset (OR 1.63, 95% CI 1.07 to 2.48; 5 trials, 848 participants), flushing (OR 4.12, 95% CI 1.83 to 9.26; 3 trials, 748 participants), and muscle aches and joint pains (OR 2.52, 95% CI 1.59 to 3.99; 4 trials, 792 participants). </p> <p>Data comparing PDE5 inhibitors to placebo whilst on other PAH‐specific therapy were limited by the small number of included trials. Those PAH participants on PDE5 inhibitors plus combination therapy walked 19.66 metres further in six minutes (95% CI 9 to 30; 4 trials, 509 participants) compared to placebo (moderate‐certainty evidence). There were limited trials comparing PDE5 inhibitors directly with other PAH‐specific therapy (endothelin receptor antagonists (ERAs)). Those on PDE5 inhibitors walked 49 metres further than on ERAs (95% CI 4 to 95; 2 trials, 36 participants) (low‐certainty evidence). There was no evidence of a difference in WHO functional class or mortality across both treatments. </p> <p>Five trials compared PDE5 inhibitors to placebo in PH secondary to left‐heart disease (PH‐LHD). The quality of data were low due to imprecision and inconsistency across trials. In those with PH‐LHD there were reduced odds of an improvement in WHO functional class using PDE5 inhibitors compared to placebo (OR 0.53, 95% CI 0.32 to 0.87; 3 trials, 285 participants), and those using PDE5 inhibitors walked 34 metres further compared to placebo (95% CI 23 to 46; 3 trials, 284 participants). There was no evidence of a difference in mortality. Five trials compared PDE5 inhibitors to placebo in PH secondary to lung disease/hypoxia, mostly in COPD. Data were of low quality due to imprecision of effect and inconsistency across trials. There was a small improvement of 27 metres in 6MWD using PDE5 inhibitors compared to placebo in those with PH due to lung disease. There was no evidence of worsening hypoxia using PDE5 inhibitors, although data were limited. Three studies compared PDE5 inhibitors to placebo or other PAH‐specific therapy in chronic thromboembolic disease. There was no significant difference in any outcomes. Data quality was low due to imprecision of effect and heterogeneity across trials. </p> </section> <section id="CD012621-sec-0007"> <h3 class="title" id="CD012621-sec-0007">Authors' conclusions</h3> <p>PDE5 inhibitors appear to have clear beneficial effects in group 1 PAH. Sildenafil, tadalafil and vardenafil are all efficacious in this clinical setting, and clinicians should consider the side‐effect profile for each individual when choosing which PDE5 inhibitor to prescribe. </p> <p>While there appears to be some benefit for the use of PDE5 inhibitors in PH‐left‐heart disease, it is not clear based on the mostly small, short‐term studies, which type of left‐heart disease stands to benefit. These data suggest possible harm in valvular heart disease. There is no clear benefit for PDE5 inhibitors in pulmonary hypertension secondary to lung disease or chronic thromboembolic disease. Further research is required into the mechanisms of pulmonary hypertension secondary to left‐heart disease, and cautious consideration of which subset of these patients may benefit from PDE5 inhibitors. Future trials in PH‐LHD should be sufficiently powered, with long‐term follow‐up, and should include invasive haemodynamic data, WHO functional class, six‐minute walk distance, and clinical worsening. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012621-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012621-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012621-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012621-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012621-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012621-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012621-abs-0005" lang="en"> <h3>PDE5 inhibitors for pulmonary hypertension</h3> <p><b>Review question:</b> </p> <p>We wanted to review whether a group of drugs called PDE5 inhibitors (which may work to open up the vessels in the lung) can help people with pulmonary hypertension (increased pressures in the blood vessels of the lungs). Cochrane researchers collected and analysed all relevant studies to answer this question, and found 36 studies. </p> <p><b>Why the review is important:</b> </p> <p>Approximately three people in every 1000 have pulmonary hypertension, due to different causes. This can lead to reduced exercise capacity, reduced quality of life, increased hospitalisations, and early death. A group of drugs called PDE5 inhibitors may improve blood circulation in the right heart and lungs. We wanted to make sure that if these drugs are being used, there is evidence of benefit and little or no harm. </p> <p><b>Main findings:</b> </p> <p>We included 36 studies with 2999 people. Trials were conducted for 14 weeks on average, with some as long as 12 months. Most trials involved adults, and two trials specifically included children. </p> <p>Nineteen trials included those with group 1 pulmonary arterial hypertension (inherited, unknown, due to connective tissue diseases). People who were given PDE5 inhibitors were compared with those not given PDE5 inhibitors. This review shows that when given PDE5 inhibitors, on average people walked 48 meters further in six minutes (8 trials, 880 people). They also improved their functional class (reducing the physical limitations associated with PH), and were less likely to die (high‐certainty evidence). They were also more likely to have side effects, including headache, flushing and muscle aches. </p> <p>Five trials included people with pulmonary hypertension due to left‐heart disease. This review shows that when given PDE5 inhibitors, these people were on average able to walk 34 metres further in six minutes (3 trials, 284 people; low‐certainty evidence). However, there was no difference in survival, compared to those who were not given PDE5 inhibitors. Five trials included people with pulmonary hypertension due to lung disease (mostly chronic obstructive pulmonary disease and some idiopathic pulmonary fibrosis). When given PDE5 inhibitors, they were able to walk 27 meters further in six minutes (low‐certainty evidence), but with no difference in survival, compared to those who were not given PDE5 inhibitors. Three trials included people with pulmonary hypertension due to blood clots; there was no significant difference in outcomes for those who used PDE5 inhibitors compared to those who did not. </p> <p><b>Limitations:</b> </p> <p>There was good‐quality evidence for those with pulmonary arterial hypertension, giving us some confidence that the results are correct. The evidence for those with pulmonary hypertension due to heart disease was less certain. The quality of evidence in this group was low because there were few trials, small numbers of people taking part, and the trials were quite different from each other, making it difficult to draw firm conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012621-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-sec-0158">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-sec-0216">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012621-sec-0158"></div> <h3 class="title" id="CD012621-sec-0159">Implications for practice</h3> <section id="CD012621-sec-0159"> <p> <ul id="CD012621-list-0016"> <li> <p>Data from this review suggest a benefit for the use of PDE5 inhibitors in group 1 PAH, for improvement in WHO functional class, reduction in clinical worsening, and improvement in haemodynamics, six‐minute walk distance, quality of life, and mortality. </p> </li> <li> <p>Sildenafil, tadalafil and vardenafil are all efficacious in this clinical setting.</p> </li> <li> <p>Clinicians may wish consider the side‐effect profile for each drug when choosing which to prescribe to an individual patient. </p> </li> <li> <p>This review suggests that a PDE5 inhibitor may be better than an ERA for six‐minute walk distance and quality of life, but that there appears to be no difference in WHO functional class or mortality. These conclusions are limited by the small number of trials. </p> </li> <li> <p>While there appears to be some benefit for the use of PDE5 inhibitors in PH‐LHD, it is not clear based on the mostly small, short‐term studies which type of left‐heart disease stands to benefit. The use of PDE5 inhibitors does not appear to be beneficial in valvular heart disease. </p> </li> <li> <p>This review suggests there is no clear benefit for PDE5 inhibitors in pulmonary hypertension secondary to lung disease or CTEPH. </p> </li> <li> <p>There may be evidence of harm in the use of PDE5 inhibitors for pulmonary hypertension secondary to sickle cell disease. </p> </li> </ul> </p> </section> <h3 class="title" id="CD012621-sec-0160">Implications for research</h3> <section id="CD012621-sec-0160"> <p> <ul id="CD012621-list-0017"> <li> <p>Further research is required into the mechanisms of pulmonary hypertension secondary to left‐heart disease. </p> </li> <li> <p>Clinical trials in PH‐LHD should be sufficiently powered, with long‐term follow‐up, and should include invasive haemodynamic data, WHO functional class, six‐minute walk distance, and clinical worsening. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012621-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012621-sec-0029"></div> <div class="table" id="CD012621-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000<br/> (204 to 549) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 8.59<br/> (3.95 to 18.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 170 ‐ 319 m<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 48 metres higher<br/> (40 higher to 56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (3 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.22<br/> (0.07 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1119<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>SF‐36: (scores 1 to 100, higher scores indicate better QoL)</p> <p>EQ‐5D questionnaire: (higher scores indicate worse QoL)</p> <p>CHFQ: (lower scores indicate worse QoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a> found a statistically significant improvement in all SF‐36 domains for sildenafil‐treated participants, and when compared to placebo in physical functioning (P &lt; 0.001), general health (P &lt; 0.001), and vitality (P &lt; 0.05). There was also a statistically significant improvement in placebo‐treated participants in the physical functioning domain. </p> <p><a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a> found statistically significant improvements for the EQ‐5D current health status (P &lt; 0.01) and utility index (P &lt; 0.01).<br/> <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a> found a statistically significant difference for the CHFQ fatigue domain (sildenafil post‐treatment score 22.33, SD 4.82 compared to placebo post‐treatment score 20.67, SD 5.19; P = 0.04), and a non‐statistically significant difference in the emotional function domain (sildenafil post‐treatment score 37.33, SD 9.3, compared to placebo post‐treatment score 34.71, SD 10.91; P = 0.06), favouring sildenafil compared with placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data considered too heterogeneous to meta‐analyse</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.43 mmHg lower (8.13 lower to 4.74 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.35 mmHg lower (2.34 lower to 0.36 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.28L/min/m<sup>2</sup> higher (0.16 higher to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.74 WU lower (6.13 lower to 3.35 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266<br/> (3 RCTs)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR. the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>EQ‐5D</b> : EuroQoL 5D; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PH</b> : pulmonary hypertension; <b>PVR</b> : pulmonary vascular resistance; <b>RAP</b> : right atrial pressure; <b>RCT</b> : randomised controlled trials; <b>SD</b> : standard deviation; <b>SF‐36</b> : Medical Outcomes Study 36‐item short form; <b>WU</b> : woods units; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Post‐treatment values for participants in the placebo group were presented in two studies only; the remaining included studies presented a mean difference only.<br/> <sup>b</sup>Downgraded due to imprecision owing to significantly high heterogeneity, although the direction of effect is consistent. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors plus other disease‐modifying therapies<br/> <b>Comparison:</b> placebo plus other disease‐modifying therapies </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo, on combination therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (191 to 437) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20<br/> (0.66 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 341 ‐ 377 m<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 metres higher<br/> (9 higher to 30 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (2 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.26<br/> (0.07 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>physical functioning on SF‐36 (higher scores indicate better quality of life)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.3 (4.7 higher to 4.1 higher)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.8 (3.6 higher to 12.1 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.58 mmHg lower<br/> (6.14 lower to 3.01 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac output</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.87 L/min higher<br/> (0.53 higher to 1.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac output, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.48 lower<br/> (0.72 lower to 0.25 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RCT</b> : randomised controlled trials; <b>SMD</b> : standardised mean difference; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision owing to small participant numbers and inconsistent direction of effect.<br/> <sup>b</sup>Range of baseline values, as studies only presented mean difference values for analysis.<br/> <sup>c</sup>Downgraded due to imprecision as the confidence interval crosses the line of no difference.<br/> <sup>d</sup>Downgraded due to imprecision owing to small participant numbers in one trial. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to ERA</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary Arterial Hypertension ‐ PDE5i compared to ERA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> endothelin receptor antagonists<b>(</b>ERA) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ERA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>325 per 1000<br/> (220 to 450) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.94<br/> (0.55 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 290 ‐ 354 m<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 49 higher<br/> (4 higher to 95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (11 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.19<br/> (0.74 to 13.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 22 higher<br/> (9 higher to 35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7.00 mmHg lower (4.82 lower to 18.82 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 mmHg higher (2.14 lower to 6.14 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 L/min/m<sup>2</sup> higher (0.49 lower to 0.49 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 WU lower (1.93 lower to 1.93 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR. the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to imprecision.<br/> <sup>b</sup>Range of baseline values, as studies only presented mean difference values for analysis.<br/> <sup>c</sup>Downgraded twice due to imprecision and small participant numbers.<br/> <sup>d</sup>Downgraded twice due to very small participant numbers and high risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 2 Pulmonary hypertension due to left‐heart disease ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to left‐heart disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000<br/> (178 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53<br/> (0.32 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 34 metres higher<br/> (23 higher to 46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (6 to 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.27 (0.28 to 5.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19.83 points higher (8.23 higher to 31.44 higher)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.05 points higher (1.14 higher to 22.96 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kansas City Cardiomyopathy Questionnaire (higher scores reflect better health status)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.17 mmHg lower<br/> (11.99 lower to 8.35 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 L/min/m<sup>2</sup> higher<br/> (0.17 lower to 0.3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to high heterogeneity and inconsistent direction of effect.<br/> <sup>b</sup>Downgraded due to imprecision as the confidence interval crosses the line of no difference.<br/> <sup>c</sup>Downgraded twice due to imprecision owing to few participant numbers in one trial. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 3 Pulmonary hypertension due to lung disease ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to lung disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/> (201 to 956) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 44.33<br/> (4.78 to 410.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 237 ‐ 297 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 27 metres higher<br/> (2 higher to 51 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.19 higher<br/> (0.07 lower to 0.44 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 overall quality of life (higher scores indicate better quality of life)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.14 mmHg lower<br/> (6.65 lower to 6.37 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 L/min/m<sup>2</sup> higher<br/> (0.14 lower to 0.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.31 WU lower<br/> (3.67 lower to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.36 mmHg higher<br/> (2.76 lower to 3.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RAP</b> : right atrial pressure; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision owing to small participant numbers.<br/> <sup>b</sup>Downgraded once due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 4 Pulmonary hypertension due to CTEPH ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to CTEPH<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with comparison (placebo/sildenafil)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 17.18<br/> (0.78 to 380.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance ‐ sildenafil compared to placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline 331 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 18 metres higher<br/> (24 lower to 59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance ‐ sildenafil compared to bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 422 ‐ 455 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 metres higher<br/> (28 lower to 69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (9 to 261) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.36 (0.22 to 8.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 lower<br/> (1.17 lower to 0.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CamPHOR scale; higher scores indicate worse quality of life</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.2 mmHg lower<br/> (12.4 lower to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.76 mmHg higher<br/> (3.96 lower to 5.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 L/min/m<sup>2</sup> higher<br/> (0.4 lower to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 L/min/m<sup>2</sup> higher<br/> (0.22 lower to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.89 WU lower<br/> (1.85 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 WU lower<br/> (0.27 lower to 0.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>CTEPH:</b> chronic thromboembolic pulmonary hypertension; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision owing to small participant numbers in only one trial.<br/> <sup>b</sup>Downgraded once due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012621-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mixed pulmonary hypertension group 2 ‐ 4 ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension group 2 ‐ 4<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 11.31<br/> (4.90 to 26.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000<br/> (438 to 806) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data provided</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 51 metres higher<br/> (7 higher to 95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10 mmHg lower<br/> (11.92 lower to 8.08 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PASP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PASP</b> : pulmonary artery systolic pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision owing to small participant numbers.<br/> <sup>b</sup>The information is from studies at low or unclear risk of bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012621-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-sec-0179">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012621-sec-0030"></div> <section id="CD012621-sec-0031"> <h3 class="title" id="CD012621-sec-0031">Description of the condition</h3> <p>Pulmonary hypertension (PH) (defined as a mean pulmonary artery pressure ≥ 25 mmHg at rest on right‐heart catheterisation) comprises a complex group of conditions (see <a href="#CD012621-tbl-0008">Table 1</a>), characterised by increased right ventricular afterload, which ultimately leads to right‐heart failure (<a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). The increased afterload may be due to passive transmission of high left‐sided pressures (post‐capillary pulmonary hypertension), obstruction of the pulmonary arterial bed (pre‐capillary pulmonary hypertension) or a combination of both. Pulmonary arterial hypertension (PAH‐WHO Group 1) is a group of diseases where pulmonary hypertension occurs in the setting of increased pulmonary vascular resistance. The more recent availability of medications and therapies targeting the pulmonary arterial bed has led to the prospect of an improvement in what had previously been a very poor prognosis. Although PAH is rare, PH secondary to left‐heart disease and lung disease is much more common. The availability of drugs with efficacy in PAH has led to great interest in the use of these drugs in other forms of pulmonary hypertension. </p> <div class="table" id="CD012621-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organisation/World Symposium classification of pulmonary hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WHO group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary arterial hypertension</p> <p> <ul id="CD012621-list-0001"> <li> <p>idiopathic PAH</p> </li> <li> <p>PAH with vasoreactivity</p> </li> <li> <p>heritable PAH</p> </li> <li> <p>drugs and toxins</p> </li> <li> <p>associated with:</p> <ul id="CD012621-list-0002"> <li> <p>connective tissue disease;</p> </li> <li> <p>HIV;</p> </li> <li> <p>portal hypertension;</p> </li> <li> <p>congenital heart disease;</p> </li> <li> <p>schistosomiasis.</p> </li> </ul> </li> </ul> </p> <p>Pulmonary veno‐occlusive disease/pulmonary capillary haemangiomatosis</p> <p>Persistent pulmonary hypertension of the newborn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pumonary hypertension due to left heart disease</p> <p> <ul id="CD012621-list-0003"> <li> <p>due to left heart failure with preserved ejection fraction</p> </li> <li> <p>due to left heart failure with reduced ejection fraction</p> </li> </ul> </p> <p>Valvular heart disease</p> <p>Congenital post‐capillary obstructive lesions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension due to chronic lung disease or chronic hypoxaemia, or both</p> <p> <ul id="CD012621-list-0004"> <li> <p>obstructive lung disease</p> </li> <li> <p>restrictive lung disease</p> </li> <li> <p>other lung diseases with a mixed obstructive/restrictive pattern</p> </li> <li> <p>sleep disordered breathing</p> </li> <li> <p>alveolar hypoventilation disorders</p> </li> <li> <p>chronic exposures to high altitudes</p> </li> <li> <p>developmental lung diseases</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension due to pulmonary artery obstruction</p> <p> <ul id="CD012621-list-0005"> <li> <p>chronic thromboembolic pulmonary hypertension</p> </li> <li> <p>other pulmonary artery obstructions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension with unclear mechanisms</p> <p> <ul id="CD012621-list-0006"> <li> <p>haematologic disorders (chronic haemolytic anaemia, myeloproliferative disorders, splenectomy) </p> </li> <li> <p>systemic disorders (sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis) </p> </li> <li> <p>metabolic disorders (glycogen storage disease, Gaucher disease, thyroid disorders)</p> </li> <li> <p>others (pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis, chronic renal failure (with/without dialysis), segmental pulmonary hypertension) </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PAH: pulmonary arterial hypertension</p> </div> </div> <p>In PAH, increased pulmonary vascular resistance is caused by vascular remodelling and thickening in the small‐ and medium‐sized arterioles, fibrinoid necrosis, the formation of eccentric, concentric, or plexiform lesions, and the loss of vascular tone. This process of cellular hypertrophy and hyperplasia is mediated by intracellular calcium and protein kinase C, inflammatory cytokines, and altered energy metabolism. Remodelling and vasoconstriction lead to hypoxia, causing further vasoconstriction and further hypoxia (<a href="./references#CD012621-bbs2-0125" title="GuignabertC , TuT , LeHiressM , RicardM , SattlerC , SeferianA . Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review2013;22(130):543‐51. ">Guignabert 2013</a>; <a href="./references#CD012621-bbs2-0141" title="SimJ . Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology2010;58(1):4‐14. ">Sim 2010</a>). </p> <p>Pulmonary hypertension is classified into five groups of multiple clinical conditions, grouped according to similar clinical presentations and pathophysiological and haemodynamic characteristics, with distinct treatment strategies for each group. Group 1 pulmonary arterial hypertension (PAH) includes idiopathic and heritable PAH and PAH due to pathology of the small pulmonary arterioles resulting from connective tissue disorders, drugs or toxins, portal pulmonary hypertension, and others (see <a href="#CD012621-tbl-0008">Table 1</a>). Pulmonary arterial hypertension is caused by increased pulmonary vascular resistance due to occlusive vasculopathy of the small pulmonary arteries and arterioles. Pulmonary arterial hypertension is a rare disease, with an estimated prevalence of 10 to 52 cases per million (<a href="./references#CD012621-bbs2-0134" title="LingY , JohnsonMK , KielyDG . Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. American Journal of Respiratory and Critical Care Medicine2012;186(8):790‐6. ">Ling 2012</a>; <a href="./references#CD012621-bbs2-0137" title="PeacockAJ , MurphyNF , McMurrayJJ , CaballeroL , StewartS . An epidemiological study of pulmonary arterial hypertension. European Respiratory Journal2007;30(1):104‐9. ">Peacock 2007</a>). However, screening for pulmonary hypertension for all causes demonstrates a prevalence of 320 cases per 100,000 (<a href="./references#CD012621-bbs2-0143" title="StrangeG , PlayfordD , StewartS , DeagueJ , NelsonH , GabbayE . Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart2012;98(4):1805‐11. ">Strange 2012</a>). </p> <p>Group 2 consists of pulmonary hypertension due to left‐heart disease, caused by increased flow through the pulmonary vasculature, or increased pulmonary pressures (e.g. mitral valve disease, left ventricular disease, and constrictive myopathies). Group 3 comprises pulmonary hypertension as a result of lung diseases or hypoxia, or both, caused by a decrease in the area of the pulmonary vascular bed (e.g. interstitial lung disease), or conditions that induce hypoxic vasoconstriction. Group 4 refers to cases of pulmonary hypertension due to chronic thromboembolic occlusion of pulmonary vasculature, and Group 5 consists of cases of pulmonary hypertension due to unclear or multifactorial mechanisms or both, including haematological, systemic, or metabolic disorders (see <a href="#CD012621-tbl-0008">Table 1</a>) (<a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). The extent to which WHO Groups 2 to 5 have pulmonary arterial bed changes analogous to WHO Group 1 (and thus respond similarly to the medications) remains unclear. Furthermore, potential detrimental effects of selective arterial vasodilatation (pulmonary oedema in WHO Group 2 and hypoxia in WHO group 3) will probably present a quite different risk/benefit profile to the same medications used in PAH. </p> <p>People with PAH often present with symptoms of dyspnoea, fatigue, syncope, and right‐heart failure (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>). Right‐heart catheterisation remains the gold standard of diagnosis to confirm pulmonary hypertension and to further investigate potential causes and treatment targets. Pulmonary arterial hypertension is defined as a mean pulmonary artery pressure equal to or greater than 25 mmHg; a pulmonary artery wedge pressure, left atrial pressure, or left ventricular end‐diastolic pressure less than or equal to 15 mmHg; and a pulmonary vascular resistance greater than three Wood units (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>). Elevation of the pulmonary artery wedge pressure suggests pulmonary hypertension secondary to left‐heart disease. People with confirmed PAH should undergo acute vasodilator testing to assess for pulmonary vasoreactivity, as a small proportion may respond very favourably to long‐term high‐dose calcium channel blocker therapy (<a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). </p> <p>Following history, examination, electrocardiogram, echocardiogram, and chest X‐ray, other investigations for people with pulmonary hypertension should include pulmonary function tests and high‐resolution computed tomography chest to assess for underlying lung disease, a ventilation/perfusion scan to assess for chronic thromboembolic pulmonary hypertension, thyroid function tests, autoimmune serology, HIV and hepatitis screening to assess for underlying aetiologies, and a six‐minute walk test or exercise testing, biomarkers to monitor response to treatment and for prognostication (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>). </p> <p>The natural history and prognosis of pulmonary hypertension varies amongst the WHO Groups. However the presence of pulmonary hypertension irrespective of WHO group generally reflects the presence of a progressive and often fatal condition. Known independent predictors of poor prognosis include advanced WHO functional class, poor performance in six‐minute walk test, high right atrial pressure, significant right ventricular dysfunction, evidence of right ventricular failure, elevated pro‐B‐type natriuretic peptide (BNP), and low cardiac index (<a href="./references#CD012621-bbs2-0144" title="ThenappanT , ShahSJ , RichS , Gomberg‐MaitlandM . A USA‐based registry for pulmonary arterial hypertension: 1982–2006. European Respiratory Journal2007;30(6):1103–10. ">Thenappan 2007</a>). </p> </section> <section id="CD012621-sec-0032"> <h3 class="title" id="CD012621-sec-0032">Description of the intervention</h3> <p>Recent years have seen the introduction of evolving therapies for PAH, with an improvement in the one‐year survival rate to 84% from 68% in the 1980s (<a href="./references#CD012621-bbs2-0108" title="ArcherSL , MichelakisED . Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. New England Journal of Medicine2009;361(19):1864‐71. ">Archer 2009</a>). The goals of therapy are to achieve a state associated with good quality of life and exercise tolerance with low mortality risk and to maintain right ventricular function, using supplemental oxygen and treatment of the underlying cause. The underlying pulmonary artery endothelial dysfunction in Group 1 PAH enables the use of PAH‐specific targeted treatments promoting vasorelaxation and suppression of cellular proliferation within the pulmonary artery wall, including nitric oxide and phosphodiesterase type 5 inhibitors (PDE5i, prostanoids, endothelin receptor antagonists, and calcium channel blockers) (<a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). </p> </section> <section id="CD012621-sec-0033"> <h3 class="title" id="CD012621-sec-0033">How the intervention might work</h3> <p>Nitric oxide performs as a pulmonary vasodilator by activating soluble guanylate cyclase, stimulating the production of cyclic guanosine monophosphate (cGMP), which in turn activates myosin light chain phosphatase, which reduces phosphorylation of myosin to reduce pulmonary vascular tone. Increased intracellular cGMP also inhibits calcium entry, thereby reducing intracellular calcium leading to less hypertrophy and hyperplasia, as well as antiproliferative and pro‐apoptotic effects that may reverse pulmonary artery remodelling. Nitric oxide also inhibits platelet recruitment, adhesion, and aggregation (<a href="./references#CD012621-bbs2-0141" title="SimJ . Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology2010;58(1):4‐14. ">Sim 2010</a>). </p> <p>However, nitric oxide administration is not without risk. High levels of inhaled nitric oxide may lead to oxidative stress and cause tissue damage, reperfusion injury, and a pulmonary inflammatory reaction. Inhaled nitric oxide is rapidly absorbed into the blood stream, where it is converted to methaemoglobin, leading to impaired rather than improved oxygen delivery (<a href="./references#CD012621-bbs2-0141" title="SimJ . Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology2010;58(1):4‐14. ">Sim 2010</a>). </p> <p>Phosphodiesterase type 5 (PDE5) specifically reduces cGMP‐degrading enzyme activity, thereby increasing cGMP production. Phosphodiesterase type 5 inhibitors are not thought to induce the same levels of oxidation as inhaled nitric oxide (<a href="./references#CD012621-bbs2-0119" title="GhofraniHA , Pepke‐ZabaJ , BarberaJA , ChannickR , KeoghAM , Gomez‐SanchezMA , et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. Journal of the American College of Cardiology2004;43(12 Suppl S):68S‐72S. ">Ghofrani 2004d</a>). Phosphodiesterase type 5 inhibitors that have been investigated for use in Group 1 PAH include sildenafil, tadalafil, and vardenafil. These agents have been shown in clinical trials to improve six‐minute walk distance and haemodynamics (<a href="./references#CD012621-bbs2-0108" title="ArcherSL , MichelakisED . Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. New England Journal of Medicine2009;361(19):1864‐71. ">Archer 2009</a>; <a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>; <a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). </p> <p>The data are less clear in WHO Group 2 to 5 patients, in whom this class of drug may be potentially harmful. There are different pathobiological and pathophysiological factors at play, leading to the development of pulmonary hypertension in these people. The nature of the pulmonary arteriopathy may be quite different (e.g. hypoxic vasoconstriction and pulmonary vascular bed obstruction in Group 3; thrombotic obstruction in Group 4). The consequences of 'selective' pulmonary arterial vasodilation may also be detrimental (pulmonary oedema in WHO group 2 and hypoxia in Group 3). Thus, as with other selective pulmonary vasodilators, a reduction in pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) by PDE5 inhibitors may not improve the overall well‐being of patients, especially in the non‐PAH Groups (2 to 5) (<a href="./references#CD012621-bbs2-0124" title="GuazziM , BorlaugB . Pulmonary hypertension due to left heart disease. Circulation2012;126(8):975‐90. ">Guazzi 2012</a>). </p> <p>Phosphodiesterase type 5 inhibitors may theoretically improve function in Group 2 patients with left‐heart disease. Previous studies in heart‐failure patients have demonstrated that nitric oxide is responsible for regulation of vascular tone, and infusion of NG‐monomethyl‐L‐arginine, an inhibitor of nitric oxide synthase, caused less vasoconstriction in heart‐failure patients compared to those with a normal pulmonary vascular resistance (<a href="./references#CD012621-bbs2-0113" title="CooperCJ , LandzbergMJ , AndersonTJ , CharbonneauF , CreagerMA , GanzP . Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation1996;93(2):266–71. ">Cooper 1996</a>). Trials using sildenafil in Group 2 pulmonary hypertension patients have shown some evidence of improvement in exercise capacity, ventilation efficiency, and quality of life (<a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>). However, other studies have demonstrated unbalanced pulmonary dilatation as a consequence of nitric oxide and analogues may lead to increased preload due to a poorly compliant left ventricle, and therefore a significant increase in pulmonary artery wedge pressure, which may even precipitate acute pulmonary oedema (<a href="./references#CD012621-bbs2-0110" title="BocchiEA , BacalF , Auler JúniorJO , CarmoneMJ , BellottiG , PileggiF . Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. American Journal of Cardiology1994;74(1):70–2. ">Bocchi 1994</a>). </p> <p>Furthermore, trials using other PAH‐specific therapies including epoprostenol and endothelin receptor antagonists in people with Group 2 pulmonary hypertension demonstrated an increased risk of hospitalisations, disease progression, and hypoxaemia. People with left ventricular dysfunction may not be able to tolerate the increased flow across a newly‐dilated pulmonary vascular bed (<a href="./references#CD012621-bbs2-0124" title="GuazziM , BorlaugB . Pulmonary hypertension due to left heart disease. Circulation2012;126(8):975‐90. ">Guazzi 2012</a>). </p> <p>People with Group 3 chronic lung diseases may experience worsening ventilation perfusion mismatch and increased hypoxaemia. A study in people with pulmonary hypertension associated with chronic obstructive pulmonary disease demonstrated an improvement in pulmonary artery pressures, but at the cost of worsening arterial oxygenation (<a href="./references#CD012621-bbs2-0109" title="BlancoI , GimenoE , MunozP , PizarroS , GistauC , Rodriguez‐RoisinR , et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2010;181(3):270–8. ">Blanco 2010</a>). </p> </section> <section id="CD012621-sec-0034"> <h3 class="title" id="CD012621-sec-0034">Why it is important to do this review</h3> <p>Given recent advances in the understanding of the pathophysiological mechanisms and treatments for pulmonary hypertension with significant contributions in the area in the last decade, we planned to summarise the current evidence relating to the use of PDE5 inhibitors in pulmonary hypertension. </p> <p>This review aimed to quantify any potential benefit for PDE5 inhibitors in people with PAH in terms of haemodynamic measurements and patient‐centred outcomes, and to balance this against any potential treatment harms, in order to guide patient preference, clinician treatment choices, and guidelines for policymakers. </p> <p>This review also examines the available evidence to determine whether there is any potential benefit or harm in using PDE5 inhibitors in people with Group 2 to 5 pulmonary hypertension. </p> <p>This review builds on a previous review (<a href="./references#CD012621-bbs2-0149" title="KanthapillaiP , WaltersEH . Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD003562.pub2] ">Kanthapillai 2004</a>), since which further concepts about pathophysiology have been developed, and a number of more recent randomised controlled trials using PDE5 inhibitors have been published. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012621-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-sec-0184">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012621-sec-0035"></div> <p>To determine the efficacy of PDE5 inhibitors for pulmonary hypertension in adults and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012621-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-sec-0185">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012621-sec-0036"></div> <section id="CD012621-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012621-sec-0038"> <h4 class="title">Types of studies</h4> <p>We include single‐ or double‐blinded randomised controlled trials (RCTs) in which PDE5 inhibitors are compared to placebo or to any other treatment. We defined 'randomised' as studies described by the author as 'randomised' anywhere in the study report. All trials defined as such, published or unpublished, in any language, were eligible for inclusion. </p> </section> <section id="CD012621-sec-0039"> <h4 class="title">Types of participants</h4> <p>We include any individual with a diagnosis of pulmonary hypertension from any cause who required medical treatment for their condition. We define pulmonary hypertension according to accepted criteria (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>; <a href="./references#CD012621-bbs2-0135" title="McLaughlinVV , ArcherSL , BadeschDB , BarstRJ , FarberHW , LindnerJR , et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents. Journal of the American College of Cardiology2009;53(17):1573–619. ">McLaughlin 2009</a>). </p> <p> <ol id="CD012621-list-0007"> <li> <p>Comparison 1 specifically assesses the effects of PDE5 inhibitors compared to placebo on Group 1 PAH, confirmed as a mean pulmonary artery pressure ≥ 25 mmHg by right‐heart catheterisation. </p> </li> <li> <p>Comparison 2 compares PDE5 inhibitors with placebo in PAH participants on combination therapy. </p> </li> <li> <p>Comparison 3 compares PDE5 inhibitors to ERAs in PAH participants.</p> </li> <li> <p>Comparison 4 includes group 2 pulmonary hypertension participants with a diagnosis of pulmonary hypertension and left‐heart disease, as defined by the authors. </p> </li> <li> <p>Comparison 5 includes group 3 pulmonary hypertension participants with a diagnosis of pulmonary hypertension and lung disease, as defined by the authors. </p> </li> <li> <p>Comparison 6 includes group 4 pulmonary hypertension participants with a diagnosis of pulmonary hypertension and chronic thromboembolic disease (CTEPH), as defined by the authors. </p> </li> <li> <p>Comparison 7 includes mixed group 2 to 5 pulmonary hypertension participants with a diagnosis of pulmonary hypertension as defined by the authors. </p> </li> </ol> </p> <p>We planned to specify subgroups of adults (older than 18 years) and a paediatric population younger than 18 years. </p> </section> <section id="CD012621-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We include studies comparing any type of PDE5 inhibitors by any route of administration with placebo or any other treatment used for pulmonary hypertension. We include studies with co‐interventions provided they are not part of the randomised treatment. We aimed to perform subgroup analyses depending on the co‐interventions used. Where studies were too heterogenous for meta‐analyses, we describe them in narrative form. </p> </section> <section id="CD012621-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012621-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012621-list-0008"> <li> <p>Change in WHO functional class</p> </li> <li> <p>Six‐minute walk distance (6MWD)</p> </li> <li> <p>Mortality</p> </li> </ol> </p> </section> <section id="CD012621-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012621-list-0009"> <li> <p>Haemodynamic parameters, including change in mean pulmonary artery pressure, change in cardiac output, cardiac index </p> </li> <li> <p>Exercise capacity other than six‐minute walk distance</p> </li> <li> <p>Quality of life/health status, by any validated scale</p> </li> <li> <p>Dyspnoea score, including visual analogue scale or Borg scale</p> </li> <li> <p>Hospitalisation/intervention</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>Reporting one or more of the outcomes listed here in the study was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD012621-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012621-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials from searches of the following databases up to 26 September 2018:</p> <p> <ol id="CD012621-list-0010"> <li> <p>The Cochrane Airways Group Register of Trials;</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) through the Cochrane Register of Studies Online (<a href="http://crso.cochrane.org" target="_blank">crso.cochrane.org</a>); </p> </li> <li> <p>MEDLINE (Ovid) 1950 to 26 September 2018;</p> </li> <li> <p>Embase (Ovid) 1974 to 26 September 2018;</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ol> </p> <p>We provide the database search strategies in <a href="./appendices#CD012621-sec-0164">Appendix 1</a>. We searched all databases from their inception to the present, with no restriction on language of publication. We searched for handsearched conference abstracts and grey literature through the CENTRAL database. </p> </section> <section id="CD012621-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all primary studies and review articles for additional references. We handsearched reference lists of included studies, relevant chapters, and review articles. We used Google to search for grey literature and conference abstracts. We translated any relevant article into English for potential inclusion. Where data were missing, we attempted to contact the trial investigators. </p> </section> </section> <section id="CD012621-sec-0047"> <h3 class="title" id="CD012621-sec-0047">Data collection and analysis</h3> <section id="CD012621-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (HB and ZB) independently screened all abstracts to determine if they met the inclusion criteria for the review. We sought full‐text publications for those papers that possibly or definitely met the inclusion criteria. Two review authors independently reviewed all full‐text articles to determine eligibility, recording reasons for ineligibility of those that did not. We resolved any disagreements through discussion, or by seeking consensus from a third review author (AB). We included a PRISMA study flow diagram in the full review to document the screening process, and included a <a href="./references#CD012621-sec-0176" title="">Characteristics of included studies</a> table (<a href="./references#CD012621-bbs2-0136" title="MoherD , LiberatiA , TetzlaffJ , AltmanD . Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>). </p> </section> <section id="CD012621-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HB and ZB) independently extracted data from included studies, and where appropriate, pooled data in the Cochrane statistical software Review Manager 5 for further analysis (<a href="./references#CD012621-bbs2-0138" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a data collection form that we piloted on one study for inclusion in the review, containing the following data. </p> <p> <ol id="CD012621-list-0011"> <li> <p>Methods: study design, duration, study setting, date of study.</p> </li> <li> <p>Participants: number, mean age and age range, gender, inclusion and exclusion criteria.</p> </li> <li> <p>Intervention: type of PDE5 inhibitor, dose, mode of administration, control drug, co‐interventions, and exclusions. </p> </li> <li> <p>Outcomes: primary and secondary outcomes as specified, type of scale used, time points collected. </p> </li> <li> <p>Risk of bias summary.</p> </li> <li> <p>Other: funding for trial, any conflicts of interest for trial authors.</p> </li> </ol> </p> </section> <section id="CD012621-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HB and ZB) independently assessed the included studies for risks of bias using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012621-bbs2-0127" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We assessed the following domains. </p> <p> <ol id="CD012621-list-0012"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential sources of bias.</p> </li> </ol> </p> <p>We judged each potential source of bias as low risk, unclear risk (insufficient information to form a judgement), or high risk, and provided justification with evidence from each trial in the ‘Risk of bias’ table. When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> <section id="CD012621-sec-0051"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the previously published protocol, and justified any deviations from it in the <a href="#CD012621-sec-0174">Differences between protocol and review</a> section of the review. </p> </section> </section> <section id="CD012621-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>Where possible, we pooled and presented results from dichotomous data as odds ratios (ORs). Where possible, we presented results from continuous variables and calculated the mean difference (MD) or standardised mean difference (SMD) where scales are combined, with the 95% confidence interval (95% CI). Where we combined data from rating scales in a meta‐analysis, we ensured that they were entered with a consistent direction of effect (e.g. lower scores always indicate improvement). If both change from baseline and endpoint scores were available for continuous data, we used change from baseline scores. Where outcomes were reported at multiple time points, we consistently extracted and included the latest reported time point, but also considered outcomes reported at other time points. We only combined data reported at different time points if this was clinically appropriate. </p> <p>We described skewed data narratively (e.g. as medians and interquartile ranges for each group). </p> <p>We used intention‐to‐treat or 'full analysis set' analyses where they were reported (i.e. those where data have been imputed for participants who were randomly assigned but did not complete the study) instead of completer or per‐protocol analyses. </p> </section> <section id="CD012621-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of children admitted to hospital, rather than number of admissions per child). Where rate ratios were reported in a study, we analysed them on that basis. We planned to only meta‐analyse data from cluster‐randomised controlled trials if the available data have been adjusted (or could be adjusted) to account for the clustering, however there were no cluster‐randomised controlled trials identified for inclusion. </p> </section> <section id="CD012621-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators in order to verify key study characteristics including methods of randomisation, and obtained missing numerical outcome data where possible (e.g. when we identified a study as an abstract only). Where this was not possible, and the missing data were thought to introduce serious bias, we took this into consideration in the GRADE rating for affected outcomes. We planned to only meta‐analyse data from cluster‐RCTs if the available data had been adjusted (or could be adjusted), to account for the clustering. </p> </section> <section id="CD012621-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>For pooled analyses we quantified statistical heterogeneity using the I<sup>2</sup> statistic, which describes the percentage of total variation across trials due to heterogeneity rather than to sampling error. We considered significant statistical heterogeneity to be present if the I<sup>2</sup> is greater than 50%. Where we identified significant heterogeneity, we attempted to explore possible causes using prespecified subgroup analyses. </p> </section> <section id="CD012621-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>Where sufficient studies were present, we planned to create and examine a funnel plot to explore small‐study and publication biases; however, there are currently insufficient studies. </p> </section> <section id="CD012621-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effects model and performed a sensitivity analysis comparing the fixed‐ and random‐effects model. Where possible we pooled dichotomous outcome variables using a Mantel‐Haenszel OR with 95% CIs. For continuous outcomes, we analysed data as MDs or standardised mean difference (SMD) where scales are combined, with the 95% confidence interval (95% CI). We calculated the number needed to treat for an additional beneficial outcome (NNTB) from the pooled OR and assumed control risk using the formula described in Section 12.5 of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD012621-bbs2-0127" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD012621-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We created seven 'Summary of findings' tables that include WHO functional class status, quality of life, mortality, change in haemodynamics, and six‐minute walk distance. We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data for the prespecified outcomes. We used the methods and recommendations described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012621-bbs2-0139" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schüneman 2017</a>), employing GRADEpro software (<a href="./references#CD012621-bbs2-0122" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 13 December 2016. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). We justified all decisions to downgrade the quality of studies using footnotes, and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> <section id="CD012621-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses:</p> <p> <ol id="CD012621-list-0013"> <li> <p>Paediatric population up to 18 years and an adult population aged 18 years or over.</p> </li> <li> <p>Dosage of PDE5 inhibitor.</p> </li> <li> <p>Mode of administration.</p> </li> </ol> </p> <p>With the following outcomes in subgroup analyses:</p> <p> <ol id="CD012621-list-0014"> <li> <p>WHO functional class.</p> </li> <li> <p>Mortality.</p> </li> <li> <p>Six‐minute walk distance.</p> </li> <li> <p>Haemodynamic criteria.</p> </li> </ol> </p> <p>However, there were insufficient studies per comparison to perform meta‐analyses for these subgroups, so we present narrative results (described in‐text where applicable). </p> </section> <section id="CD012621-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses:</p> <p> <ul id="CD012621-list-0015"> <li> <p>Exclusion of trials identified as being at high risk of selection bias (described in‐text where applicable). </p> </li> <li> <p>Fixed‐effect model compared with random‐effects model (presented in table form).</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012621-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012621-sec-0061"></div> <section id="CD012621-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012621-sec-0063"> <h4 class="title">Results of the search</h4> <p>We identified 4840 citations in the initial search, and after screening abstracts, selected 136 studies for full‐text review. We included 36 trials with 2999 participants in the final review, plus earlier published abstracts, further post hoc analyses and analyses of secondary outcomes (see <a href="#CD012621-fig-0001">Figure 1</a>). We also found five ongoing studies (see <a href="./references#CD012621-sec-0178" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD012621-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012621-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012621-sec-0064"> <h4 class="title">Included studies</h4> <section id="CD012621-sec-0065"> <h5 class="title">Group 1: Pulmonary arterial hypertension</h5> <p>We included all but two of the 36 studies in the final meta‐analysis; <a href="./references#CD012621-bbs2-0018" title="JalalianR , MoghadamniaAA , TamaddoniA , KhafriS , IranianM . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassaemia intermedia. Heart Lung and Circulation2016;14(26):677–83. JalalianR , TammadoniA , IranianM , SaraviM , MohgadamniaA , KhafiSE . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassemia intermedia. European Heart Journal2015;36:502. ">Jalalian 2015</a> included participants with pulmonary hypertension secondary to sickle cell disease, and <a href="./references#CD012621-bbs2-0021" title="GladwinM , MachadoR , HassellK , YovetichN , GordeukV , GibbsS , et al. Treatment of pulmonary hypertension (PH) and sickle cell disease (scd) with sildenafil (sild) therapy (walk‐phasst): interim report. European Respiratory Society 19th Annual Congress; 2009 September 12‐15; Vienna, Austria. 2009; Vol. 171. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the walk‐PHaSST trial. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans (LA). 2010:A2514. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Safety and efficacy of sildenafil therapy for doppler‐defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk‐PHaSST clinical trial. Blood2009;114(22):Abstract no: 571. YovetichNA , HassellKL , MachadoRF , BarstRJ , GladwinMT . Treatment of pulmonary hypertension and sickle cell disease with sildenafil therapy (walk‐PHaSST): Background, rationale, study design, current enrollment and baseline data. American Journal of Hematology Conference: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting; 2009 Feb 15‐20; Fort Lauderdale (FL). 2009:E197‐8. ">Machado 2009</a> included participants with pulmonary hypertension secondary to beta‐thalassemia, and was stopped early due to increased adverse events in the treatment arm. All studies were randomised; 30 were parallel‐controlled and six were cross‐over trials. </p> <p>Nineteen trials included group 1 PAH participants (<a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a>; <a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a> (specifically Eisenmenger's syndrome); <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; (<a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a> ‐ specifically children with PAH); <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>). Most trials recruited participants with WHO functional class II and III (see <a href="./references#CD012621-sec-0176" title="">Characteristics of included studies</a>). </p> <p>Eleven trials in PAH participants compared a PDE5 inhibitor to placebo: seven trials compared sildenafil to placebo (<a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a>), three compared tadalafil to placebo (<a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>), and one compared vardenafil to placebo (<a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>). </p> <p>Four studies compared PDE5 inhibitors to placebo, whilst on additional combination therapy (all as add‐on therapy) (<a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>), and four studies (<a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a>; <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a>; <a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a>) compared PDE5 inhibitors to endothelin receptor antagonists. </p> <p>In the PAH trials, sildenafil was prescribed in eight hourly divided doses, with dosages ranging from 20 to 100 mg three times daily. Where multiple doses were compared, we used results from the highest dose where appropriate (e.g. haemodynamics), and aggregated doses where appropriate (e.g. mortality). Tadalafil was dosed 2.5 to 40 mg daily and vardenafil 5 mg twice daily. The duration of trials ranged from two weeks to 12 months, with a mean treatment duration of 14 weeks. </p> <p>In PAH participants, the primary outcomes of six‐minute walk distance (6MWD) was reported in 15 trials (<a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>), WHO functional class improvement in seven of 19 trials (<a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>), and mortality in 13 of 19 trials (<a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>). Haemodynamic data were reported in 12 of 19 trials (<a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>), For quality of life, two trials used the SF‐36 form (scores 1 to 100, higher scores indicate better quality of life) (<a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>); minimum clinical improvement difference (MCID) for physical functioning domain for PAH = 13, vitality = 15 (<a href="./references#CD012621-bbs2-0121" title="GilbertC , BrownMC , CappelleriJC , CarlssonM , McKennaSP . Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest2009;135(1):137‐42. ">Gilbert 2009</a>). One used a heart failure questionnaire (<a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>), where the higher the score the better the quality of life, and one (<a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a>) used the Kansas City Cardiomyopathy Questionnaire, where higher scores indicated better quality of life. Six trials measured dyspnoea using the Borg dyspnoea scale (MCID for PAH = 1 (<a href="./references#CD012621-bbs2-0131" title="KhairRM , NwaneriC , DamicoRL , KolbT , HassounPM , MathaiSC . The minimal important difference in borg dyspnea score in pulmonary arterial hypertension. Annals of the American Thoracic Society2016;13(6):842‐9. ">Khair 2016</a>)) (<a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>). Eleven studies reported adverse events (<a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a>; <a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a>). </p> </section> <section id="CD012621-sec-0066"> <h5 class="title">Group 2: Pulmonary hypertension due to left‐heart disease</h5> <p>Five trials included PH secondary to left‐heart disease (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a> (valvular heart disease); <a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a> (HFpEF); <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a> (HFpEF); <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a> (systolic heart failure); <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a> (diastolic heart failure)). Heart failure was reported as optimally treated according to accepted guidelines at the time of enrolment. All five trials used sildenafil 25 to 75 mg three times daily compared to placebo. Three trials had a 12‐week duration, one trial was for six months (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>), and one trial (<a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a>) had a 12‐month duration. In terms of primary outcomes, three of the five reported improvement in WHO functional class (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>; <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a>; <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>), three of the five reported 6MWD (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>; <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>; <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a>), and three of the five reported mortality (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>; <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a>; <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>). Haemodynamic data were assessed using right‐heart catheterisation in three of the five trials (<a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a>; <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a>; <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>), and pulmonary artery systolic pressure (PASP) using transthoracic ultrasound in one trial (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>). Quality of life was reported in one trial (<a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a>) using the Kansas City Cardiomyopathy Questionnaire (23 items, a higher score indicating better quality of life), and one trial (<a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a>) reported dyspnoea. Two trials reported adverse events, including exacerbation of heart failure (<a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a>; <a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a>). </p> </section> <section id="CD012621-sec-0067"> <h5 class="title">Group 3: Pulmonary hypertension due to lung disease</h5> <p>Five trials included PH secondary to lung disease, predominantly that of COPD (<a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a>; <a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a>; <a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>; <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a>), and one with IPF (<a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a>). The duration was 12 to 16 weeks (median 12 weeks). Four compared sildenafil to placebo (<a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a>; <a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a>; <a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>; <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a>) and one (<a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a>) compared tadalafil to placebo. The primary outcomes of improvement in WHO functional class were reported in only one trial (<a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>); 6MWD in all five trials, and no trials reported mortality. Only two trials (<a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>; <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a>) reported haemodynamic data. <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a> reported quality of life using SFGRQ (although this was reported using median and IQR) and SF‐36. <a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a> reported SF‐36 and Minnesota Questionnaire. <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a> reported SF‐36 and BODE index. No trials reported dyspnoea. Three trials reported adverse events, although insufficient data were provided to produce a meta‐analysis. </p> </section> <section id="CD012621-sec-0068"> <h5 class="title">Group 4: Chronic thromboembolic pulmonary hypertension</h5> <p>Three trials included CTEPH participants (<a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>). All trials used sildenafil, with two (<a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>) comparing to placebo, and <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a> comparing to bosentan. Trial duration was a mean of 3.5 months. Improvement in functional class was reported in one study, 6MWD in all three studies, mortality in all three studies, and haemodynamic data in all three studies. One study (<a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>) measured quality of life using the CAMPHOR scale (higher scores indicate worse quality of life), and also reported dyspnoea using the Borg scale. Only one study reported adverse events. </p> </section> <section id="CD012621-sec-0069"> <h5 class="title">Mixed group 2 to 4 pulmonary hypertension</h5> <p>Two trials enrolled participants with PH across WHO Groups 2 and 3 (<a href="./references#CD012621-bbs2-0008" title="DwivediP , NarainVS , SaranRK , DwivediSK , SethiR , ChandraS , et al. Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension. Indian Heart Journal2015;67:S128. ">Dwivedi 2015</a>; <a href="./references#CD012621-bbs2-0028" title="SalemM , DiabA , AteyaA , SanadO . Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egyptian Heart Journal2014;66(1):49‐53. ">Salem 2013</a>), including participants with secondary pulmonary hypertension due to COPD, heart failure, valvular heart disease, and cardiomyopathy. Sildenafil 20 to 50 mg three times daily was compared to placebo. Only improvement in functional class, 6MWD, and PASP were reported. </p> </section> <section id="CD012621-sec-0070"> <h5 class="title">Group 5: Haematological disorders</h5> <p>Two trials included participants with PH secondary to haematological disorders (<a href="./references#CD012621-bbs2-0021" title="GladwinM , MachadoR , HassellK , YovetichN , GordeukV , GibbsS , et al. Treatment of pulmonary hypertension (PH) and sickle cell disease (scd) with sildenafil (sild) therapy (walk‐phasst): interim report. European Respiratory Society 19th Annual Congress; 2009 September 12‐15; Vienna, Austria. 2009; Vol. 171. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the walk‐PHaSST trial. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans (LA). 2010:A2514. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Safety and efficacy of sildenafil therapy for doppler‐defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk‐PHaSST clinical trial. Blood2009;114(22):Abstract no: 571. YovetichNA , HassellKL , MachadoRF , BarstRJ , GladwinMT . Treatment of pulmonary hypertension and sickle cell disease with sildenafil therapy (walk‐PHaSST): Background, rationale, study design, current enrollment and baseline data. American Journal of Hematology Conference: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting; 2009 Feb 15‐20; Fort Lauderdale (FL). 2009:E197‐8. ">Machado 2009</a> (sickle cell disease); <a href="./references#CD012621-bbs2-0018" title="JalalianR , MoghadamniaAA , TamaddoniA , KhafriS , IranianM . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassaemia intermedia. Heart Lung and Circulation2016;14(26):677–83. JalalianR , TammadoniA , IranianM , SaraviM , MohgadamniaA , KhafiSE . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassemia intermedia. European Heart Journal2015;36:502. ">Jalalian 2015</a> (beta‐thalassemia)). We analysed these trials descriptively and separately. </p> </section> </section> <section id="CD012621-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded 65 studies for the following reasons: ineligible participant population (6); ineligible intervention (13); ineligible study design (22); extension of a previous study (9); post‐hoc analysis (15) (see <a href="./references#CD012621-sec-0177" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD012621-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risks of bias in the included studies using the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012621-bbs2-0128" title="HigginsJP , AltmamDG , Sterne JA(editors) , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), and included the domains of allocation, blinding, incomplete outcome data, selective reporting, and other potential sources of bias. Please see <a href="#CD012621-fig-0002">Figure 2</a> for a summary of the 'Risk of bias' findings. </p> <div class="figure" id="CD012621-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012621-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012621-sec-0073"> <h4 class="title">Allocation</h4> <p>We assessed random sequence generation as low risk for 23 studies. <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0018" title="JalalianR , MoghadamniaAA , TamaddoniA , KhafriS , IranianM . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassaemia intermedia. Heart Lung and Circulation2016;14(26):677–83. JalalianR , TammadoniA , IranianM , SaraviM , MohgadamniaA , KhafiSE . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassemia intermedia. European Heart Journal2015;36:502. ">Jalalian 2015</a>; <a href="./references#CD012621-bbs2-0021" title="GladwinM , MachadoR , HassellK , YovetichN , GordeukV , GibbsS , et al. Treatment of pulmonary hypertension (PH) and sickle cell disease (scd) with sildenafil (sild) therapy (walk‐phasst): interim report. European Respiratory Society 19th Annual Congress; 2009 September 12‐15; Vienna, Austria. 2009; Vol. 171. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the walk‐PHaSST trial. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans (LA). 2010:A2514. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Safety and efficacy of sildenafil therapy for doppler‐defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk‐PHaSST clinical trial. Blood2009;114(22):Abstract no: 571. YovetichNA , HassellKL , MachadoRF , BarstRJ , GladwinMT . Treatment of pulmonary hypertension and sickle cell disease with sildenafil therapy (walk‐PHaSST): Background, rationale, study design, current enrollment and baseline data. American Journal of Hematology Conference: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting; 2009 Feb 15‐20; Fort Lauderdale (FL). 2009:E197‐8. ">Machado 2009</a>; <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a> were at unclear risk, as they did not report methods of random sequence generation. </p> <p>We assessed allocation concealment as low risk for 26 studies and unclear risk for <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0008" title="DwivediP , NarainVS , SaranRK , DwivediSK , SethiR , ChandraS , et al. Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension. Indian Heart Journal2015;67:S128. ">Dwivedi 2015</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>, as allocation concealment was not reported. We assessed <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a> and <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a> as high risk, as each study was reported as an open‐label study. </p> </section> <section id="CD012621-sec-0074"> <h4 class="title">Blinding</h4> <p>We assessed <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>; <a href="./references#CD012621-bbs2-0028" title="SalemM , DiabA , AteyaA , SanadO . Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egyptian Heart Journal2014;66(1):49‐53. ">Salem 2013</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>; <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a> as being at unclear risk, as blinding of participants and personnel was not clearly reported. <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a> and <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a> were assessed as being at high risk as the trials were reported as open‐label studies, so it was likely that participants knew which intervention they were receiving. </p> <p>We assessed <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0008" title="DwivediP , NarainVS , SaranRK , DwivediSK , SethiR , ChandraS , et al. Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension. Indian Heart Journal2015;67:S128. ">Dwivedi 2015</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0018" title="JalalianR , MoghadamniaAA , TamaddoniA , KhafriS , IranianM . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassaemia intermedia. Heart Lung and Circulation2016;14(26):677–83. JalalianR , TammadoniA , IranianM , SaraviM , MohgadamniaA , KhafiSE . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassemia intermedia. European Heart Journal2015;36:502. ">Jalalian 2015</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a>; <a href="./references#CD012621-bbs2-0028" title="SalemM , DiabA , AteyaA , SanadO . Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egyptian Heart Journal2014;66(1):49‐53. ">Salem 2013</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>; <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a>; <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a> as being at unclear risk of detection bias, as methods for blinding of outcomes were not clearly reported. We assessed <a href="./references#CD012621-bbs2-0022" title="MazzantiG , AlbiniA , PalazziniM , MontiE , BachettiC , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH). European Society of Cardiology Annual Congress; 2013 Aug 31‐Sep 4; Amsterdam, Netherlands. 2013:A3535. MazzantiG , PalazziniM , DardiF , TerziF , D'AdamoA , RinaldiA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension. European Society of Congress; 2012 Aug 25‐29; Munchen, Germany. 2012:A4105. MazzantiG , PalazziniM , LeciE , DardiF , RinaldiA , D'AdamoA , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long‐term results. American Journal of Respiratory and Critical Care Medicine2013;187:A3535. ">Mazzanti 2013</a> as being at high risk, as this trial was reported as open‐label and there were no specified methods to keep outcomes blinded from assessors. </p> </section> <section id="CD012621-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed attrition bias as unclear risk in 15 studies: <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0010" title="GalièN , BeardsworthA , WrishkoRE , GhofraniHA . Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval. American Thoracic Society International Conference; 2009 May 15‐20; San Diego (CA). 2009:A1045. ">Galiè 2009</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a>; <a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a>; <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a>; <a href="./references#CD012621-bbs2-0023" title="MukhopadhyayS , NathaniS , YusufJ , ShrimalD , TyagiS . Clinical efficacy of phosphodiesterase‐5 inhibitor tadalafil in Eisenmenger Syndrome‐A randomized, placebo‐controlled, double‐blind crossover study. Congenital Heart Disease2011;6(5):424‐31. ">Mukhopadhyay 2011</a>; <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a>; <a href="./references#CD012621-bbs2-0028" title="SalemM , DiabA , AteyaA , SanadO . Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egyptian Heart Journal2014;66(1):49‐53. ">Salem 2013</a>; <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>; <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>; <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>, given that only a proportion of participants who were enrolled completed the study, for reasons which were not given; however, this included both intervention and comparator arms in approximately equal proportions. </p> <p>For <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a> and <a href="./references#CD012621-bbs2-0008" title="DwivediP , NarainVS , SaranRK , DwivediSK , SethiR , ChandraS , et al. Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension. Indian Heart Journal2015;67:S128. ">Dwivedi 2015</a>, about one‐third of enrolled participants did not complete the study, for unknown reasons, so we assigned this a high risk of bias. For <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a>, the number of enrolled participants and the number of completers were not reported, so we rated this at high risk. </p> </section> <section id="CD012621-sec-0076"> <h4 class="title">Selective reporting</h4> <p>We found reporting bias to be high risk in <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>, as only one outcome was reported. <a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a> was a substudy of the STEP‐IPF trial, and it is not clear if this analysis was planned a priori so we assessed it as high risk. <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a> only reported quantitative data from the intervention group and not from the comparator group, and no between‐group effect sizes were reported, so we rated it at high risk. <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a> reported that they only assessed secondary outcomes if the primary outcomes were significant, although it is unclear if this affected the overall reporting of the trial outcomes, as a number of secondary outcomes were reported; we assessed this as high risk of bias. </p> </section> <section id="CD012621-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a>; <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a>; <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; and <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a> as unclear risk of other bias, as these were abstracts from conference proceedings, and were not recorded in any clinical trials registry, with limited information about methods used and limited data presented to determine if other significant risk was present. </p> </section> </section> <section id="CD012621-sec-0078"> <h3 class="title" id="CD012621-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD012621-tbl-0001"><b>Summary of findings for the main comparison</b> Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</a>; <a href="./full#CD012621-tbl-0002"><b>Summary of findings 2</b> Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</a>; <a href="./full#CD012621-tbl-0003"><b>Summary of findings 3</b> Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to ERA</a>; <a href="./full#CD012621-tbl-0004"><b>Summary of findings 4</b> Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i compared to placebo</a>; <a href="./full#CD012621-tbl-0005"><b>Summary of findings 5</b> Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i compared to placebo</a>; <a href="./full#CD012621-tbl-0006"><b>Summary of findings 6</b> Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i compared to placebo</a>; <a href="./full#CD012621-tbl-0007"><b>Summary of findings 7</b> Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i compared to placebo</a> </p> <section id="CD012621-sec-0079"> <h4 class="title">Group 1: Pulmonary arterial hypertension</h4> <section id="CD012621-sec-0080"> <h5 class="title">PDE5 inhibitors compared to placebo</h5> <section id="CD012621-sec-0081"> <h6 class="title">Change in WHO functional class</h6> <p>Four studies assessed change in WHO functional class (Comparison 1). There was a significant improvement in WHO functional class favouring PDE5 inhibitors when compared to placebo, (odds ratio (OR) 8.59, 95% CI 3.95 to 18.72; P &lt; 0.001; 4 trials, 282 participants; I<sup>2</sup> = 0%; <a href="./references#CD012621-fig-0009" title="">Analysis 1.1</a>; see <a href="#CD012621-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012621-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.1 Improvement in WHO functional class." data-id="CD012621-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.1 Improvement in WHO functional class. </p> </div> </div> </div> </section> <section id="CD012621-sec-0082"> <h6 class="title">Six‐minute walk distance</h6> <p>Eight studies assessed 6MWD. There was a significant improvement in 6MWD using PDE5 inhibitors compared to placebo (mean difference between PDE5i and placebo (MD) 48 metres, 95% CI 40 to 56; P &lt;0.001; 8 trials, 880 participants; <a href="./references#CD012621-fig-0010" title="">Analysis 1.2</a>). The effect was clinically significant, with a mean difference of 48 metres (MCID in PAH is 41 metres (<a href="./references#CD012621-bbs2-0121" title="GilbertC , BrownMC , CappelleriJC , CarlssonM , McKennaSP . Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest2009;135(1):137‐42. ">Gilbert 2009</a>)). The effect on 6MWD was comparable between drugs (sildenafil MD 57 metres, 95% CI 44 to 69; P &lt; 0.001; 4 trials, 339 participants; tadalafil MD 38 metres, 95% CI 28 to 49; P &lt; 0.001; 3 trials, 477 participants; vardenafil MD 69 metres, 95% CI 41 to 97; P &lt; 0.001; 1 trial, 64 participants). There was significant heterogeneity between trials (I<sup>2</sup> = 71; P = 0.03), which is not fully explained by the different drugs used in each trial (subgroup difference I<sup>2</sup> = 51%; P = 0.03). </p> </section> <section id="CD012621-sec-0083"> <h6 class="title">Mortality</h6> <p>There was a significant effect on mortality using PDE5 inhibitors compared to placebo (OR 0.22, 95% CI 0.07 to 0.68, P = 0.009; 8 trials, 1119 participants; <a href="./references#CD012621-fig-0011" title="">Analysis 1.3</a>; see <a href="#CD012621-fig-0004">Figure 4</a>). In the placebo group four people out of 100 died, compared to one (95% CI 0 to 3) out of 100 for the PDE5 inhibitor group; see <a href="#CD012621-fig-0005">Figure 5</a>. The number needed to treat to prevent one additional death was 32 (95% CI 27 to 78). </p> <div class="figure" id="CD012621-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.3 Mortality." data-id="CD012621-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.3 Mortality. </p> </div> </div> </div> <div class="figure" id="CD012621-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Cates Plot for mortality with PDE5 inhibitor treatment in Group 1 PAH" data-id="CD012621-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cates Plot for mortality with PDE5 inhibitor treatment in Group 1 PAH</p> </div> </div> </div> </section> <section id="CD012621-sec-0084"> <h6 class="title">Haemodynamics</h6> <p>There was a significant reduction in the mean PAP (MD −6.43 mmHg, 95% CI −8.13 to −4.74; P &lt; 0.001; 6 trials, 453 participants; <a href="./references#CD012621-fig-0012" title="">Analysis 1.4</a>), in the right arterial pressure (RAP) (MD −1.35 mmHg, 95% CI −2.34 to −0.36; P = 0.008; 3 trials, 341 participants; <a href="./references#CD012621-fig-0013" title="">Analysis 1.5</a>), in cardiac index (MD 0.28 L/min/m<sup>2</sup>, 95% CI 0.16 to 0.40; P &lt; 0.001; 4 trials, 239 participants; <a href="./references#CD012621-fig-0014" title="">Analysis 1.6</a>), in PVR (MD −4.74 WU, 95% CI −6.13 to −3.35; P &lt; 0.0001; 3 trials, 266 participants; <a href="./references#CD012621-fig-0015" title="">Analysis 1.7</a>), and in PASP (MD −11.62 mmHg, 95% CI −25.18 to 1.94; P = 0.09; 2 trials, 48 participants; <a href="./references#CD012621-fig-0016" title="">Analysis 1.8</a>). There was significant heterogeneity between trials for mean PAP (I<sup>2</sup> = 76%; P = 0.01). However, the test for subgroup difference was not significant (P = 0.23; I<sup>2</sup> = 31%), suggesting that factors other than different drugs across trials may account for this heterogeneity. There was also significant heterogeneity for cardiac index (I<sup>2</sup> = 77%; P = 0.005). The test for subgroup difference (P = 0.03; I<sup>2</sup> = 82%) indicated that the difference between different drugs used may account for this heterogeneity. </p> </section> <section id="CD012621-sec-0085"> <h6 class="title">Exercise capacity other than six‐minute walk distance</h6> <p>Two studies assessed exercise capacity. <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a> examined time on treadmill (using the Naughton protocol) and found a statistically significant difference favouring sildenafil with post‐treatment sildenafil 686.82 metres (SD 224.02) compared to placebo 475.05 metres (SD 168.02; P &lt; 0.001). <a href="./references#CD012621-bbs2-0031" title="SinghT , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double blind, cross‐over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension. Indian Heart Journal2005;57(5):Abstract no:533. SinghTP , RohitM , GroverA , MalhotraS , VijayvergiyaR . A randomized, placebo‐controlled, double‐blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. American Heart Journal2006;151(4):851.e1‐5. ">Singh 2006</a> assessed Mets achieved using a modified Bruce exercise protocol. There was a statistically significant difference favouring sildenafil post‐treatment 687 seconds (SD 243.9 sec) compared to placebo 452.1 seconds (SD 165.6 sec) (P &lt; 0.001). </p> </section> <section id="CD012621-sec-0086"> <h6 class="title">Quality of life</h6> <p>Only two studies assessed quality of life, and data were considered too heterogenous to combine in a meta‐analysis. <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a> assessed quality of life using two measures: the Medical Outcomes Study 36‐item short form (SF‐36), divided into physical functioning, general health, and vitality domains (scores 1 to 100, higher scores indicate better quality of life), and found a statistically significant improvement in all SF‐36 domains for sildenafil‐treated participants, and when compared to placebo in physical functioning (P &lt; 0.001), general health (P &lt; 0.001), and vitality (P &lt; 0.05). There was also a statistically significant improvement in placebo‐treated participants in the physical functioning domain. They also used the EuroQol 5D (EQ‐5D) questionnaires at baseline and after 12 and 24 weeks of treatment (comprise five dimensions: mobility, self‐care, usual activities, pain/discomfort and anxiety/depression; higher scores indicate worse quality of life). Statistically significant improvements were also observed for the EQ‐5D current health status (P &lt; 0.01) and utility index (P &lt; 0.01). </p> <p><a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a> assessed quality of life using a chronic heart failure questionnaire, includes the following domains: dyspnoea, fatigue, and emotional function of daily living; lower scores indicate worse quality of life. There was a statistically significant difference in the fatigue domain (sildenafil post‐treatment score 22.33, SD 4.82 compared to placebo post‐treatment score 20.67, SD 5.19; P = 0.04), and a statistically non‐significant difference in the emotional function domain (sildenafil post‐treatment score 37.33, SD 9.3, compared to placebo post‐treatment score 34.71, SD 10.91; P = 0.06), favouring sildenafil compared with placebo. </p> </section> <section id="CD012621-sec-0087"> <h6 class="title">Dyspnoea</h6> <p>Five trials assessed dyspnoea: four (<a href="./references#CD012621-bbs2-0004" title="BharaniA , MathewV , SahuA , LuniaB . The efficacy and tolerability of sildenafil in patients with moderate‐to‐severe pulmonary hypertension. Indian Heart Journal2003;55(1):55‐9. ">Bharani 2003</a>; <a href="./references#CD012621-bbs2-0005" title="BharaniA , PatelA , SarafJ , JainA , MehrotraS , LuniaB . Efficacy and safety of PDE‐5 inhibitor tadalafil in pulmonary arterial hypertension. Indian Heart Journal2007;59(4):323‐8. ">Bharani 2007</a>; <a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a>; <a href="./references#CD012621-bbs2-0019" title="JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil therapy for pulmonary arterial hypertension: A randomised, double‐blind, placebo‐controlled, multicenter study. European Society of Cardiology, ESC Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. JingZC , YuZX , ShenJY , WuBX , XuKF , ZhuXY , et al. Vardenafil in pulmonary arterial hypertension: a randomized, double‐blind, placebo‐controlled study. American Journal of Respiratory and Critical Care Medicine2011;183(12):1723‐9. ">Jing 2011</a>) used the Borg scale and one (<a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a>) used a chronic heart failure questionnaire. When we combined the studies using Borg scale, there was a statistically significant improvement in dyspnoea (MD −0.72, 95% CI −0.99 to −0.44; P &lt; 0.001; 4 studies, 239 participants; <a href="./references#CD012621-fig-0017" title="">Analysis 1.9</a>), but the effect size did not meet the minimum clinical improvement difference (MCID = 1, <a href="./references#CD012621-bbs2-0131" title="KhairRM , NwaneriC , DamicoRL , KolbT , HassounPM , MathaiSC . The minimal important difference in borg dyspnea score in pulmonary arterial hypertension. Annals of the American Thoracic Society2016;13(6):842‐9. ">Khair 2016</a>). There was significant heterogeneity across trials (I<sup>2</sup> = 64%; P = 0.04), but the test for subgroup differences (I<sup>2</sup> = 37%; P = 0.20) suggests that factors other than different drugs may account for differences across the trials. </p> </section> <section id="CD012621-sec-0088"> <h6 class="title">Hospitalisation/intervention</h6> <p>Three trials (746 participants) reported clinical worsening requiring intervention, including hospitalisation and initiation or addition of new therapy. There was no statistically significant difference, although the effect estimate favoured PDE5 inhibitors compared to placebo (OR 0.58, 95% CI 0.27 to 1.23; P = 0.16; <a href="./references#CD012621-fig-0018" title="">Analysis 1.10</a>). </p> </section> <section id="CD012621-sec-0089"> <h6 class="title">Adverse events</h6> <p>There were more adverse events in the PDE5 inhibitor participants compared to placebo (<a href="./references#CD012621-fig-0019" title="">Analysis 1.11</a>). </p> <p>There was a statistically significant increase in headache (OR 1.97, 95% CI 1.33 to 2.92; P &lt; 0.001; 5 studies, 848 participants), in gastrointestinal (GI) upset (OR 1.63, 95% CI 1.07 to 2.48; P = 0.02; 5 studies, 848 participants), in flushing (OR 4.12, 95% CI 1.83 to 9.26; P &lt; 0.001; 3 studies, 748 participants), and in muscle aches and joint pains (OR 2.52, 95% CI 1.59 to 3.99; P &lt; 0.001; 4 studies, 792 participants). </p> <p>There was no statistically significant difference in epistaxis (OR 2.37, 95% CI 0.83 to 6.77; P = 0.11; 2 studies, 682 participants), in respiratory symptoms (OR 1.74, 95% CI 0.89 to 3.40; P = 0.10; 3 studies, 748 participants), or in visual disturbance (OR 2.04, 95% CI 0.58 to 7.14; P = 0.27; 3 studies, 748 participants). </p> <p>Although different formulation of drugs were not compared head‐to‐head, when comparing the odds of developing an adverse event, tadalafil appeared to cause greater frequency of headaches (OR 2.86, 95% CI 1.51 to 5.42; P = 0.001) compared to sildenafil (OR 1.43, 95% CI 0.83 to 2.44; P = 0.20), greater GI upset (OR 1.93, 95% CI 1.07 to 3.50; P = 0.03) compared to sildenafil (OR 1.50, 95% CI 0.81 to 2.78; P = 0.19), and greater frequency of muscle and joint pains (OR 4.02, 95% CI 2.05 to 7.89; P &lt; 0.001) compared to sildenafil (OR 1.48, 95% CI 0.93 to 2.99; P = 0.27). </p> <p><b>Subgroup analyses</b> </p> <p>There were no individual patient data to compare outcomes for a paediatric population versus an adult population. <a href="./references#CD012621-bbs2-0026" title="PaliiI , VatamanE , ManiucL , RepinO , VatamanM , CucuI . Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic‐to‐pulmonary shunts and RV dysfunction. European Heart Journal2011;32(Issue suppl_1, 113):P759. PaliiI , VatamanE , RevencoN , ManiucL , VatamanM , Repin . Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double‐blind, randomised controlled study. Archives of Disease in Childhood2014;99(suppl 2):A31. PaliiI , VatamanE , StratulatP . Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic‐to‐pulmonary shunts. European Heart Journal2013;34:39. ">Palii 2014</a> recruited only children with PAH due to congenital cardiac shunts and found benefit in improvement in functional class, mortality (5 of 39 died at 6 to 12 months in the placebo group compared to none of 38 in the sildenafil group), improved exercise tolerance, and improved haemodynamics. <a href="./references#CD012621-bbs2-0002" title="BarstR , IvyD , GaitanG , SzatmariA , RudzinskiA , GarciaA , et al. A randomized, double‐blind, placebo‐controlled, dose‐ranging study of oral sildenafil citrate in treatment‐naive children with pulmonary arterial hypertension. Circulation2012;125(2):324‐34. ">Barst 2012</a> recruited only children with pulmonary arterial hypertension, and found no significant difference in terms of exercise duration or cardiopulmonary haemodynamics. </p> <p>Almost all trials included participants with WHO functional class II/III. <a href="./references#CD012621-bbs2-0007" title="BoonstraA , BurgessG , ParpiaT , TorbickiA . Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes. European Respiratory Journal2005;26:3619. ">Boonstra 2005</a> compared participants with WHO FC I/II and III/IV and found that the six‐minute walk distance improved in both groups (49 metres improvement in WHO FC I/II (n = 27) and 54 metres improvement in WHO FC III/IV (n = 42)). </p> </section> </section> <section id="CD012621-sec-0090"> <h5 class="title">PDE5 inhibitors compared to placebo on additional therapy</h5> <p>Four trials compared PDE5 inhibitors to placebo, whilst on other therapy for pulmonary hypertension (Comparison 2). <a href="./references#CD012621-bbs2-0017" title="IversenK , JensenAS , JensenTV , VejlstrupNG , SondergaardL . Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo‐controlled, double‐blinded trial. European Heart Journal2010;31(9):1124‐31. ">Iversen 2009</a> and <a href="./references#CD012621-bbs2-0034" title="VizzaC , LansaP , TealS , DombiT , ZhouD . Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovascular Disorders2017;17(1):239‐52. ">Vizza 2017a</a> compared sildenafil to placebo as add‐on therapy to bosentan. <a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a> compared sildenafil to placebo as add‐on therapy to intravenous epoprostenol. <a href="./references#CD012621-bbs2-0036" title="ZhuangY , JiangB , GaoH , ZhaoW . Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertension Research2014;37(6):507‐12. ">Zhuang 2014</a> compared tadalafil to placebo as add‐on therapy to ambrisentan. </p> <section id="CD012621-sec-0091"> <h6 class="title">Change in WHO functional class</h6> <p>There was no significant difference in WHO functional class (OR 1.20, 95% CI 0.66 to 2.17; P = 0.55; 2 trials, 227 participants; <a href="./references#CD012621-fig-0020" title="">Analysis 2.1</a>). </p> </section> <section id="CD012621-sec-0092"> <h6 class="title">Six‐minute walk distance</h6> <p>There was a statistically significant difference in 6MWD using PDE5 inhibitors compared to placebo as add‐on therapy (MD 20, 95% CI 9 to 30; P &lt; 0.001; 4 trials, 509 participants; <a href="./references#CD012621-fig-0021" title="">Analysis 2.2</a>), but this did not meet the MCID threshold (41 metres; <a href="./references#CD012621-bbs2-0121" title="GilbertC , BrownMC , CappelleriJC , CarlssonM , McKennaSP . Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest2009;135(1):137‐42. ">Gilbert 2009</a>). </p> </section> <section id="CD012621-sec-0093"> <h6 class="title">Mortality</h6> <p>There was no statistically significant difference in mortality using PDE5 inhibitors compared to placebo as add‐on therapy (OR 0.26, 95% CI 0.07 to 1.06; P = 0.06; 3 trials, 492 participants; <a href="./references#CD012621-fig-0022" title="">Analysis 2.3</a>). </p> </section> <section id="CD012621-sec-0094"> <h6 class="title">Haemodynamics</h6> <p>There was a statistically significant reduction in mean PAP (MD −4.58 mmHg, 95% CI −6.14 to −3.01; P &lt; 0.001; 2 trials, 387 participants; <a href="./references#CD012621-fig-0023" title="">Analysis 2.4</a>), and in PVR (SMD −0.48, 95% CI −0.72 to −0.25; P &gt; 0.001; 3 trials, 303 participants; <a href="./references#CD012621-fig-0025" title="">Analysis 2.6</a>) and a statistically significant increase in cardiac output (MD 0.87 L/min, 95% CI 0.53 to 1.21; P &lt; 0.001; 3 trials, 310 participants; <a href="./references#CD012621-fig-0024" title="">Analysis 2.5</a>) using sildenafil compared to placebo as add‐on therapy. </p> </section> <section id="CD012621-sec-0095"> <h6 class="title">Exercise capacity other than six‐minute walk distance</h6> <p>No studies reported additional exercise testing.</p> </section> <section id="CD012621-sec-0096"> <h6 class="title">Quality of life</h6> <p>One trial (<a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>) assessed quality of life using SF‐36. There was a significant improvement in the sildenafil group in terms of physical functioning (MD 0.3, 95% CI 4.7 to 4.1 for placebo versus MD 7.8, 95% CI 3.6 to 12.1 for sildenafil; P = 0.003), general health (MD 1.4, 95% CI 4.8 to 2.1 versus MD 6.6, 95% CI 3.3 to 9.9; P = 0.001), vitality (MD 0.8, 95% CI 3.3 to 4.9 versus MD 10.2, 95% CI 6.2 to 14.2; P = 0.001), social functioning (MD 2.5, 95% CI 7.8 to 2.9 versus MD 4.0, 95% CI 1.1 to 9.2; P = 0.05), and mental health (MD 3.7, 95% CI 7.0 to 0.5 versus MD 3.0, 95% CI 0.1 to 6.2; P = 0.001), but not in physical role (MD 3.6, 95% CI 5.4 to 12.7 versus MD 10.7, 95% CI 2.0 to 19.4; P = 0.20), bodily pain (MD 0.6, 95% CI 4.3 to 5.5 versus MD 5.8, 95% CI 1.0 to 10.6; P = 0.09), or emotional role (MD 4.6, 95% CI 4.2 to 13.5 versus MD 1.8, 95% CI 6.8 to 10.3; P = 0.60). </p> </section> <section id="CD012621-sec-0097"> <h6 class="title">Dyspnoea</h6> <p>No studies assessed the effect on dyspnoea.</p> </section> <section id="CD012621-sec-0098"> <h6 class="title">Hospitalisation/intervention</h6> <p>Four studies assessed clinical worsening requiring hospitalisation or additional therapy. There was a statistically significant difference favouring PDE5 inhibitors compared to placebo as add‐on therapy (OR 0.38, 95% CI 0.21 to 0.68; P = 0.001; 4 trials, 717 participants; <a href="./references#CD012621-fig-0026" title="">Analysis 2.7</a>). </p> </section> <section id="CD012621-sec-0099"> <h6 class="title">Adverse events</h6> <p>There was a statistically significant increased risk of headache (OR 2.49, 95% CI 1.74 to 3.56; P &lt; 0.001; 5 studies, 768 participants), GI upset (OR 1.95, 95% CI 1.30 to 2.93; P = 0.001; 4 studies, 726 participants), muscle and joint pain (OR 2.17, 95% CI 1.28 to 3.67; P = 0.004; 3 studies, 494 participants), and visual disturbance (OR 3.95, 95% CI 0.97 to 16.08; P = 0.06; 2 studies, 368 participants). There was no statistically significant difference in flushing (OR 1.11, 95% CI 0.63 to 1.96; P = 0.71; 2 studies, 368 participants) or epistaxis (OR 1.32, 95% CI 0.34 to 5.12; P = 0.69; 2 studies, 358 participants) <a href="./references#CD012621-fig-0027" title="">Analysis 2.8</a>. </p> </section> </section> <section id="CD012621-sec-0100"> <h5 class="title">PDE5 inhibitors compared to endothelin receptor antagonists (ERA)</h5> <p>Three trials compared PDE5 inhibitors head‐to‐head with an endothelin receptor antagonist (Comparison 3): <a href="./references#CD012621-bbs2-0001" title="AlbiniA , DardiF , RinaldiA , MontiE , TaneseN , GottiE , et al. Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine2017;195:A3112. ">Albini 2017</a> compared monotherapy (ambrisentan or tadalafil) with combination therapy; for the purpose of this meta‐analysis ambrisentan was compared to tadalafil. <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a> compared ambrisentan monotherapy with tadalafil monotherapy with combination therapy; for this meta‐analysis, ambrisentan 10 mg daily monotherapy was compared to tadalafil 40 mg daily monotherapy. <a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a> compared sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily) with bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily). </p> <section id="CD012621-sec-0101"> <h6 class="title">Change in WHO functional class</h6> <p>There was no significant difference in WHO functional class (OR 0.94, 95% CI 0.55 to 1.60; P = 0.82; 1 trial, 244 participants; <a href="./references#CD012621-fig-0028" title="">Analysis 3.1</a>). </p> </section> <section id="CD012621-sec-0102"> <h6 class="title">Six‐minute walk distance</h6> <p>There was a statistically and clinically significant difference in 6MWD favouring sildenafil compared to bosentan (MD 49 metres, 95% CI 4 to 95; P = 0.03; 2 trials, 36 participants; <a href="./references#CD012621-fig-0029" title="">Analysis 3.2</a>). As <a href="./references#CD012621-bbs2-0011" title="GalièN , BarberaJA , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. AMBITION: A randomised, multicenter study of first‐line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). European Respiratory Journal2014;44(Suppl 58):2916. GalièN , BarberaJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. HoeperM , GalièN , BarberaJ A , FrostA , GhofraniA , McLaughlinV , et al. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. European Respiratory Journal2015;46(Suppl 59):OA4994. RubinL , BarberaJ , FrostA , GhofraniHA , HoeperM , McLaughlinV , et al. Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study. Chest2014;146(4 suppl 2):339A. ThiererJ . In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial. Revista Argentina de Cardiologia2015;83(5):487‐93. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;181:A2197. VachieryJL , GalièN , BarberaJA , FrostA , GhofraniHA , HoeperMM , et al. Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial. American Journal of Respiratory and Critical Care Medicine2015;191:A2197. ">Galiè 2015</a> reported 6MWD as median and IQR, it was not possible to include it in the meta‐analysis (<a href="./references#CD012621-bbs2-0127" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). The median change from baseline distance in the tadalafil group was 23 metres (IQR −8 to 66) compared to the ambrisentan group 27 metres (IQR −14 to 63). </p> </section> <section id="CD012621-sec-0103"> <h6 class="title">Mortality</h6> <p>There was no significant difference in mortality comparing PDE5 inhibitors to ERA (OR 3.19, 95% CI 0.74 to 13.64; P = 0.12; 2 trials, 272 participants; <a href="./references#CD012621-fig-0030" title="">Analysis 3.3</a>). </p> </section> <section id="CD012621-sec-0104"> <h6 class="title">Haemodynamics</h6> <p>There was no significant difference in haemodynamics in one small study (32 participants), including mean PAP (MD 7.00, 95% CI −4.82 to 18.82; P = 0.25), RAP (MD 2.00, 95% CI −2.14 to 6.14; P = 0.34), cardiac index (MD 0.00, 95% CI −0.49 to 0.49; P = 1.00), and PVR (MD 0.00, 95% CI −1.93 to 1.93; P = 1.00). <a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a> assessed participants using cardiac magnetic resonance imaging (MRI) and found no significant difference in cardiac index (MD 0 L/min/m<sup>2</sup>, 95% CI −0.2 to 0.2). </p> </section> <section id="CD012621-sec-0105"> <h6 class="title">Exercise capacity other than six‐minute walk distance</h6> <p>No studies reported additional exercise testing.</p> </section> <section id="CD012621-sec-0106"> <h6 class="title">Quality of life</h6> <p>One study (<a href="./references#CD012621-bbs2-0035" title="WilkinsMR , PaulGA , StrangeJW , TunariuN , Gin‐SingW , BanyaWA , et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. American Journal of Respiratory and Critical Care Medicine2005;171(11):1292‐7. ">Wilkins 2005</a>) found a significant difference in quality of life favouring sildenafil compared to bosentan using the Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) (MD 22.00, 95% CI 9.00 to 35.00; P = 0.009). </p> </section> <section id="CD012621-sec-0107"> <h6 class="title">Dyspnoea</h6> <p>No studies assessed dyspnoea.</p> </section> <section id="CD012621-sec-0108"> <h6 class="title">Hospitalisation/intervention</h6> <p>There was a statistically significant incidence of clinical worsening in the ERA group compared to the PDE5 inhibitor group (OR 0.52, 95% CI 0.30 to 0.89; P = 0.02; 2 trials, 275 participants; <a href="./references#CD012621-fig-0036" title="">Analysis 3.9</a>). </p> </section> <section id="CD012621-sec-0109"> <h6 class="title">Adverse events</h6> <p>Only one trial assessed adverse events (<a href="./references#CD012621-fig-0037" title="">Analysis 3.10</a>). There was no significant difference in headache (OR 1.10, 95% CI 0.65 to 1.87; P = 0.72), GI upset (OR 0.79, 95% CI 0.42 to 1.45; P = 0.44), flushing (OR 0.60, 95% CI 0.27 to 1.33; P = 0.21), muscle or joint pain (OR 1.34, 95% CI 0.60 to 3.00; P = 0.47), or respiratory symptoms (OR 0.80, 95% CI 0.47 to 1.35; P = 0.40). </p> </section> </section> </section> <section id="CD012621-sec-0110"> <h4 class="title">Group 2: Pulmonary hypertension due to left‐heart disease</h4> <p>Five trials assessed participants with pulmonary hypertension secondary to left‐heart disease (Comparison 4). All trials compared sildenafil with placebo. </p> <section id="CD012621-sec-0111"> <h5 class="title">Change in WHO functional class</h5> <p>Significantly fewer people receiving sildenafil improved in WHO functional class compared to placebo (OR 0.53, 95% CI 0.32 to 0.87; P = 0.01; 3 trials, 285 participants; <a href="./references#CD012621-fig-0038" title="">Analysis 4.1</a>), although there was considerable heterogeneity between trials (I<sup>2</sup> = 67%, P = 0.05). </p> </section> <section id="CD012621-sec-0112"> <h5 class="title">Six‐minute walk distance</h5> <p>Three studies assessed the 6MWD. There was a significant difference favouring sildenafil (MD 34 metres, 95% CI 23 to 46; P &lt; 0.001; 3 studies, 284 participants; <a href="./references#CD012621-fig-0039" title="">Analysis 4.2</a>; see <a href="#CD012621-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD012621-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), outcome: 4.2 Six‐minute walk distance." data-id="CD012621-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), outcome: 4.2 Six‐minute walk distance. </p> </div> </div> </div> </section> <section id="CD012621-sec-0113"> <h5 class="title">Mortality</h5> <p>Three studies assessed mortality. There was no significant difference between sildenafil and placebo (OR 1.27, 95% CI 0.28 to 5.80; P = 0.76; 3 trials, 286 participants; <a href="./references#CD012621-fig-0040" title="">Analysis 4.3</a>). </p> </section> <section id="CD012621-sec-0114"> <h5 class="title">Haemodynamics</h5> <p>There was a significant reduction in mean PAP (MD −10.17 mmHg, 95% CI −11.99 to −8.35; P &lt; 0.001, although with significant heterogeneity (I<sup>2</sup> = 98%, P &lt; 0.001); 3 trials, 130 participants; <a href="./references#CD012621-fig-0041" title="">Analysis 4.4</a>), transpulmonary pressure gradient (TPG) (MD −14.60 mmHg, 95% CI −15.63 to −13.57; P &lt; 0.001; 1 trial, 44 participants; <a href="./references#CD012621-fig-0043" title="">Analysis 4.6</a>), and PASP (MD −27.60 mmHg, 95% CI −30.37 to −24.83; P &lt; 0.001; 1 trial, 44 participants; <a href="./references#CD012621-fig-0045" title="">Analysis 4.8</a>) using sildenafil compared to placebo. There was no significant difference in cardiac index (MD 0.07 L/min/m<sup>2</sup>, 95% CI −0.17 to 0.30; P = 0.59; 2 trials, 96 participants; <a href="./references#CD012621-fig-0042" title="">Analysis 4.5</a>) or RAP (MD −1.00 mmHg, 95% CI −3.77 to 1.77; P = 0.48; 1 trial, 34 participants; <a href="./references#CD012621-fig-0044" title="">Analysis 4.7</a>). <a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a> reported results in median and IQR so we could not combine the data in the meta‐analysis, but there was no significant difference in haemodynamic parameters measured by Doppler echocardiography or magnetic resonance. </p> </section> <section id="CD012621-sec-0115"> <h5 class="title">Exercise capacity other than six‐minute walk distance</h5> <p>Two studies reported exercise capacity testing. <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a> reported no significant difference in VO<sub>2</sub> peak (treatment effect sildenafil MD 0.2 mL/kg/min<sup>‐1</sup> (95% CI ‐0.9 to 1.4) compared to placebo MD 0.70 mL/kg/min<sup>‐1</sup> (95% CI −0.3 to 1.6); P = 0.51). <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a> reported a statistically significant difference in VO<sub>2</sub> peak favouring sildenafil (post‐treatment sildenafil MD 1.8 ± 0.7 mL/kg/min<sup>‐1</sup> compared to placebo MD 0.27 mL/kg/min<sup>‐1</sup>; P = 0.02). </p> </section> <section id="CD012621-sec-0116"> <h5 class="title">Quality of life</h5> <p>One study (<a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a>) assessed quality of life using the Kansas City Cardiomyopathy Questionnaire (KCCQ: higher scores reflect better health status). The mean change in the KCCQ clinical summary score from baseline to 12 weeks was 12.05 points higher (95% CI 1.14 to 22.96) in the sildenafil group and 19.83 points higher (95% CI 8.23 to 31.44) in the placebo group, although the difference was not significant (P = 0.32). </p> </section> <section id="CD012621-sec-0117"> <h5 class="title">Dyspnoea</h5> <p>One study (<a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a>) assessed dyspnoea using the 16‐item Chronic Heart Failure Questionnaire (CHQ) (<a href="./references#CD012621-bbs2-0126" title="GuyattGH , Veldhuyzen Van ZantenSJ , FeenyDH , PatrickDL . Measuring quality of life in clinical trials: a taxonomy and review. Canadian Medical Association Journal1989;140(12):1441‐8. ">Guyatt 1989</a>). There was a significant improvement in dyspnoea using sildenafil compared to placebo (MD 1.15, 95% CI 0.51 to 1.79; P &lt; 0.001; 1 trial, 44 participants; <a href="./references#CD012621-fig-0046" title="">Analysis 4.9</a>). </p> </section> <section id="CD012621-sec-0118"> <h5 class="title">Hospitalisation/intervention</h5> <p>There were mixed results in terms of clinical worsening requiring intervention including hospitalisation. <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a> (PH with systolic dysfunction) reported no significant difference in clinical worsening (OR 0.32, 95% CI 0.05 to 1.95; P = 0.22; 34 participants; <a href="./references#CD012621-fig-0047" title="">Analysis 4.10</a>), but <a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a> (valvular heart disease) reported an increased risk of hospitalisations, particularly relating to heart failure in those treated with sildenafil compared to placebo (OR 1.43; 95% CI 0.76 to 2.70; P = 0.05; 200 participants). </p> </section> <section id="CD012621-sec-0119"> <h5 class="title">Adverse events</h5> <p>Three studies reported adverse events. In <a href="./references#CD012621-bbs2-0020" title="LewisGD , LachmannJ , CamusoJ , LeporeJJ , ShinJ , MartinovicME , et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation2007;115(1):59‐66. LewisGD , ShahR , ShahzadK , CamusoJM , PappagianopoulosPP , HungJ , et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation2007;116(14):1555‐62. ">Lewis 2007</a> the incidence of headache occurred more commonly in those treated with sildenafil compared to placebo (1 trial; P &lt; 0.05) but there was no significant difference in terms of arrhythmias, hypotension, diarrhoea, flushing, or myalgia, and no incidence of visual disturbance. <a href="./references#CD012621-bbs2-0016" title="HoendermisES , LiuLC , HummelYM , Van derMeerP , DeBoerRA , BergerRMF , et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal2015;36(36):2565‐73. LiuLC , HummelYM , Van derMeerP , BergerRM , DammanK , VanVeldhuisenDJ , et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure2017;19(1):116‐25. ">Hoendermis 2015</a> reported that adverse events occurred in 22 participants (85%) who received sildenafil and 21 participants (81%) who received placebo (P = 1.00). Prevalence of known adverse effects of sildenafil, such as headache, dyspepsia, (orthostatic) hypotension, increased erection and respiratory tract infection, were reported to be higher in the sildenafil group, but event data were not supplied. <a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a> reported an increased risk of gastrointestinal events (OR 2.82, 95% CI 0.91 to 10.41; P = 0.06), and infections (OR 0.22, 95% 0.02 to 1.13; P = 0.05). </p> </section> </section> <section id="CD012621-sec-0120"> <h4 class="title">Group 3: Pulmonary hypertension due to lung disease</h4> <p>Five trials included participants with pulmonary hypertension secondary to lung disease or hypoxaemia; in four trials this was secondary to COPD, and in one trial secondary to IPF (Comparison 5) (<a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a>) . Four trials compared sildenafil to placebo, and one trial (<a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a>) compared tadalafil to placebo. </p> <section id="CD012621-sec-0121"> <h5 class="title">Change in WHO functional class</h5> <p>One trial assessed improvement in WHO functional class, and found a statically significant improvement using sildenafil compared with placebo (OR 44.33, 95% CI 4.78 to 410.93; P &lt; 0.001; 40 participants; <a href="./references#CD012621-fig-0048" title="">Analysis 5.1</a>). </p> </section> <section id="CD012621-sec-0122"> <h5 class="title">Six‐minute walk distance</h5> <p>There was a significant improvement in the 6MWD with the use of sildenafil compared to placebo (MD 27 metres, 95% CI 2 to 51; P &lt; 0.001; 5 trials, 350 participants; <a href="./references#CD012621-fig-0049" title="">Analysis 5.2</a>; see <a href="#CD012621-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD012621-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Group 3 Pulmonary Hypertension due to lung disease, outcome: 5.2 Six‐minute walk distance." data-id="CD012621-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Group 3 Pulmonary Hypertension due to lung disease, outcome: 5.2 Six‐minute walk distance. </p> </div> </div> </div> </section> <section id="CD012621-sec-0123"> <h5 class="title">Mortality</h5> <p>No studies assessed mortality.</p> </section> <section id="CD012621-sec-0124"> <h5 class="title">Haemodynamics</h5> <p>There was no significant difference in terms of mean PAP (MD −0.14 mmHg, 95% CI −6.65 to 6.37; P = 0.97; 2 trials, 61 participants; <a href="./references#CD012621-fig-0051" title="">Analysis 5.4</a>), cardiac index (MD 0.30 L/min/m<sup>2</sup>, 95% CI −0.14 to 0.74; P = 0.18; 1 trial, 28 participants; <a href="./references#CD012621-fig-0052" title="">Analysis 5.5</a>), RAP (MD 0.36 mmHg, 95% CI −2.76 to 3.48; P = 0.82; 1 trial, 28 participants; <a href="./references#CD012621-fig-0054" title="">Analysis 5.7</a>) and PVR (MD −1.31 mmHg, 95% CI −3.67 to 1.05; P = 0.28; 1 trial, 28 participants; <a href="./references#CD012621-fig-0053" title="">Analysis 5.6</a>). </p> </section> <section id="CD012621-sec-0125"> <h5 class="title">Exercise capacity other than six‐minute walk distance</h5> <p><a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a> reported exercise capacity after three months pulmonary rehabilitation and treatment with sildenafil or placebo. There was no difference in the placebo‐corrected difference in the cycle endurance time: −7 seconds, 90% CI −540 to 244; P = 0.77, or maximal exercise tolerance 1 watt, 90% CI −2 to 5; P = 0.60. </p> </section> <section id="CD012621-sec-0126"> <h5 class="title">Quality of life</h5> <p>Three studies assessed quality of life. <a href="./references#CD012621-bbs2-0013" title="GoudieA , HopkinsonP , LipworthB , StruthersA . Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study). European Respiratory Society 23rd Annual Congress; 2013 September 7‐11; Barcelona, Spain. 2013. GoudieA , LipworthB , HopkinsonP , WeiL , StruthersA . Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double‐blind, parallel‐group, placebo‐controlled trial. Lancet Respiratory Medicine2014;2(4):293–300. ">Goudie 2014</a> used SF‐36 (lower scores indicate worse quality of life), and <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a> assessed the BODE index and the Minnesota Questionnaire. <a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a> used the St George's Respiratory Questionnaire (SGRQ), the EuroQOL, and the SF‐36. We pooled data for the SF‐36 physical function, and demonstrated no significant difference in overall quality of life (MD 0.19, 95% CI −0.07 to 0.44; P = 0.15; 2 trials, 238 participants; <a href="./references#CD012621-fig-0050" title="">Analysis 5.3</a>). <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a> reported outcomes using mean and IQR, so results could not be pooled in the meta‐analysis. There was no significant difference in SGRQ score (placebo‐corrected difference median 1.3, IQR −3.5 to 6.9, P = 0.53), or SF‐36 physical score (median −1.7, IQR −7.2 to 2.3, P = 0.38), or SF‐36 mental score (median 1.6, IQR −3.7 to 8.5 P = 0.64). </p> </section> <section id="CD012621-sec-0127"> <h5 class="title">Dyspnoea</h5> <p>No studies assessed dyspnoea.</p> </section> <section id="CD012621-sec-0128"> <h5 class="title">Hospitalisation/intervention</h5> <p>No studies assessed clinical worsening.</p> </section> <section id="CD012621-sec-0129"> <h5 class="title">Adverse events</h5> <p>Three trials reported adverse events, but none reported event data that could be pooled in a meta‐analysis. <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a> reported that adverse events were similar across groups. <a href="./references#CD012621-bbs2-0027" title="RaoRS , SinghS , SharmaBB , AgarwalVV , SinghV . Sildenafil improves six‐minute walk distance in chronic obstructive pulmonary disease: a randomised, double‐blind, placebo‐controlled trial. Indian Journal of Chest Diseases and Allied Sciences2011;53(2):81‐5. RaoRS , SinghS , SharmaBB , SinghV . Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial. European Respiratory Society 19th Annual Congress; 2009 Sep 12‐15; Vienna, Austria. 2009:P3850. ">Rao 2011</a> reported that headache was the most common side effect with sildenafil. Other adverse effects noted were epigastric pain or discomfort, headache, paraesthesias, and numbness. <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a> reported that adverse events were observed in five participants in the sildenafil arm. The events were mild to moderate and included headache, diarrhoea, flushing, limb pain, dyspnoea, myalgia, and peripheral oedema. None interrupted the study treatment because of adverse events. No significant adverse effects were reported in the placebo arm. Two studies reported oxygenation parameters. <a href="./references#CD012621-bbs2-0033" title="VituloP , CallariA , MartinoL , StanziolaA , OggionniT , MeloniF , et al. Spheric‐1 (sildenafil and pulmonary hypertension in COPD): Intention‐to‐treat (ITT) analysis of safety and efficacy data. Journal of Heart and Lung Transplantation2014;33(4):S148‐9. VituloP , SofiaM , ConfalonieriM , LibertucciD Oggionni , RottoliP , et al. COPD‐associated severe pulmonary hypertension (COPDPH): Results of a 16‐weeks prospective multicenter, double‐blind, placebo‐controlled randomized clinical trial (RCT) (SPHERIC‐1 (clinicaltrials.gov/ct2/show/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. European Respiratory Journal2013;42(Suppl 57):5151. VituloP , StanziolaA , ConfalonieriM , LibertucciD , OggionniT , RottoliP , et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. Journal of Heart and Lung Transplantation2016;36(2):166‐74. ">Vitulo 2016</a> reported no difference in SpO<sub>2</sub> or PaO<sub>2</sub> in the sildenafil group from the start to the end of the study. <a href="./references#CD012621-bbs2-0006" title="BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. European Respiratory Journal2013;42(4):982‐92. BlancoI , SantosS , GeaJ , GuellR , TorresF , Gimeno‐SantosE , et al. Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial. American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)2013;187:A2266. ">Blanco 2013</a> reported no significant differences in arterial oxygen tension or saturation between the sildenafil and placebo groups. </p> </section> </section> <section id="CD012621-sec-0130"> <h4 class="title">Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)</h4> <p>Three trials included CTEPH participants (<a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a>; <a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>; Comparison 6). All trials used sildenafil, two (<a href="./references#CD012621-bbs2-0025" title="PalazziniM , LeciE , BachettiC , SgroF , MazzantiG , BecianiE , et al. A randomized open label study comparing bosentan or sildenafil first‐line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Society of Cardiology Congress; 2010 Aug 28‐Sep 1; Stockholm, Sweden. 2010. ">Palazzini 2010</a>; <a href="./references#CD012621-bbs2-0032" title="SuntharalingamJ , TreacyCM , DoughtyNJ , GoldsmithK , SoonE , ToshnerMR , et al. Long‐term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest2008;134(2):229‐36. ">Suntharalingham 2008</a>) compared to placebo, and <a href="./references#CD012621-bbs2-0012" title="GalièN , GottiE , PalazziniM , ManesA , BachettiC , MazzantiG , et al. A randomized open label study comparing first‐line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine2016;193:A6468. ">Galiè 2016a</a> compared to bosentan. </p> <section id="CD012621-sec-0131"> <h5 class="title">Change in WHO functional class</h5> <p>Only one trial examined improvement in WHO functional class in CTEPH participants, and found no significant difference in the use of PDE5 inhibitors compared to placebo (OR 17.18, 95% CI 0.78 to 380.84; P = 0.07; 1 trial, 19 participants; <a href="./references#CD012621-fig-0055" title="">Analysis 6.1</a>). </p> </section> <section id="CD012621-sec-0132"> <h5 class="title">Six‐minute walk distance</h5> <p>There was no significant difference in 6MWD using PDE5 inhibitors when compared to placebo (MD 18 metres, 95% CI −24 to 59; P = 0.41; 1 trial, 19 participants; <a href="./references#CD012621-fig-0056" title="">Analysis 6.2</a>; see <a href="#CD012621-fig-0008">Figure 8</a>) or when compared to bosentan (MD 20 metres, 95% CI −28 to 69; P = 0.41; 2 trials, 227 participants). </p> <div class="figure" id="CD012621-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 Group 4 Pulmonary Hypertension due to CTEPH, outcome: 6.2 Six‐minute walk distance." data-id="CD012621-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 Group 4 Pulmonary Hypertension due to CTEPH, outcome: 6.2 Six‐minute walk distance. </p> </div> </div> </div> </section> <section id="CD012621-sec-0133"> <h5 class="title">Mortality</h5> <p>There were no deaths in either arm in one trial comparing sildenafil with placebo (20 participants). There was no significant difference in mortality in one trial comparing PDE5 inhibitors to bosentan (OR 1.36, 95% CI 0.22 to 8.48; P = 0.74; 106 participants; <a href="./references#CD012621-fig-0057" title="">Analysis 6.3</a>). </p> </section> <section id="CD012621-sec-0134"> <h5 class="title">Haemodynamics</h5> <p>There was no difference in haemodynamic parameters. There was no difference in mean PAP using PDE5 inhibitors when compared to placebo (MD −6.20 mmHg, 95% CI −12.40 to −0.00; P = 0.05; 1 trial, 19 participants; <a href="./references#CD012621-fig-0058" title="">Analysis 6.4</a>) or when compared to bosentan (MD 0.76 mmHg, 95% CI −3.96 to 5.48; P = 0.75; 2 trials, 227 participants). There was no difference in cardiac index using PDE5 inhibitors when compared to placebo (MD 0.00 L/min/m<sup>2</sup>, 95% CI −0.40 to 0.40; P = 1.0; 1 trial, 19 participants; <a href="./references#CD012621-fig-0059" title="">Analysis 6.5</a>) or when compared to bosentan (MD 0.04 L/min/m<sup>2</sup>, 95% CI −0.22 to 0.31; P = 0.76; 2 trials, 227 participants). There was no difference in PVR using PDE5 inhibitors when compared to placebo (MD −0.89, 95% CI −1.85 to 0.06; P = 0.07; 1 trial, 19 participants; <a href="./references#CD012621-fig-0060" title="">Analysis 6.6</a>) or when compared to bosentan (MD −0.01, 95% CI −0.27 to 0.25; P = 0.96; 2 trials, 227 participants). There was no difference in RAP using PDE5 inhibitors when compared to placebo (MD −0.90 mmHg, 95% CI −6.10 to 4.30; P = 0.73; 1 trial, 19 participants; <a href="./references#CD012621-fig-0061" title="">Analysis 6.7</a>) or when compared to bosentan (MD −1.00 mmHg, 95% CI −3.77 to 1.77; P = 0.48; 1 trial, 121 participants). </p> </section> <section id="CD012621-sec-0135"> <h5 class="title">Exercise capacity other than six‐minute walk distance</h5> <p>No studies reported exercise capacity testing.</p> </section> <section id="CD012621-sec-0136"> <h5 class="title">Quality of life</h5> <p>Only one trial examined quality of life, using the CamHOR scale (higher scores indicate worse quality of life). There was no significant difference (MD −0.26, 95% CI −1.17 to 0.64; P = 0.57; 34 participants; <a href="./references#CD012621-fig-0062" title="">Analysis 6.8</a>). </p> </section> <section id="CD012621-sec-0137"> <h5 class="title">Dyspnoea</h5> <p>No trials assessed dyspnoea.</p> </section> <section id="CD012621-sec-0138"> <h5 class="title">Hospitaisation/intervention</h5> <p>No trials examined clinical worsening.</p> </section> <section id="CD012621-sec-0139"> <h5 class="title">Adverse events</h5> <p>There were no significant differences in terms of headache (OR 2.57, 95% CI 0.19 to 34.47; P = 0.48; 19 participants; <a href="./references#CD012621-fig-0063" title="">Analysis 6.9</a>) or GI upset (OR 4.50, 95% CI 0.37 to 54.16; P = 0.24; 19 participants) between PDE5‐inhibitors and placebo in one trial. </p> </section> </section> <section id="CD012621-sec-0140"> <h4 class="title">Mixed group 2 to 4 pulmonary hypertension</h4> <p>We combined two studies in this meta‐analysis: <a href="./references#CD012621-bbs2-0028" title="SalemM , DiabA , AteyaA , SanadO . Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension. Egyptian Heart Journal2014;66(1):49‐53. ">Salem 2013</a>, which included participants with secondary pulmonary hypertension due to valvular heart disease, chronic thromboembolic disease, COPD, IPF, and idiopathic dilated cardiomyopathy, and <a href="./references#CD012621-bbs2-0008" title="DwivediP , NarainVS , SaranRK , DwivediSK , SethiR , ChandraS , et al. Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension. Indian Heart Journal2015;67:S128. ">Dwivedi 2015</a>, which included participants with symptomatic secondary PAH including idiopathic dilated cardiomyopathy, heart failure with preserved ejection fraction, COPD, and other lung parenchymal disease, and valvular heart disease (Comparison 7). </p> <section id="CD012621-sec-0141"> <h5 class="title">Change in WHO functional class</h5> <p>There was a significant improvement in WHO functional class favouring PDE5 inhibitors (OR 11.31, 95% CI 4.90 to 26.14; P &lt; 0.001; 2 trials, 146 participants; <a href="./references#CD012621-fig-0064" title="">Analysis 7.1</a>). </p> </section> <section id="CD012621-sec-0142"> <h5 class="title">Six‐minute walk distance</h5> <p>There was a significant difference in 6MWD in one trial favouring PDE5 inhibitors (MD 51 metres, 95% CI 7 to 95; P=0.02; 106 participants; <a href="./references#CD012621-fig-0065" title="">Analysis 7.2</a>). </p> </section> <section id="CD012621-sec-0143"> <h5 class="title">Mortality</h5> <p>No trials assessed mortality.</p> </section> <section id="CD012621-sec-0144"> <h5 class="title">Haemodynamics</h5> <p>There was a significant improvement in PASP (MD −10.00 mmHg, 95% CI −11.92 to −8.08; P &lt; 0.001; 2 trials, 146 participants; <a href="./references#CD012621-fig-0066" title="">Analysis 7.3</a>). No other haemodynamic parameters were measured. </p> </section> <section id="CD012621-sec-0145"> <h5 class="title">Exercise capacity other than six‐minute walk distance</h5> <p>No studies reported exercise capacity testing.</p> </section> <section id="CD012621-sec-0146"> <h5 class="title">Quality of life</h5> <p>No trials assessed quality of life.</p> </section> <section id="CD012621-sec-0147"> <h5 class="title">Dyspnoea</h5> <p>No trials assessed dyspnoea.</p> </section> <section id="CD012621-sec-0148"> <h5 class="title">Hospitalisation/intervention</h5> <p>No trials assessed clinical worsening.</p> </section> <section id="CD012621-sec-0149"> <h5 class="title">Adverse events</h5> <p>No trials reported adverse events.</p> </section> <section id="CD012621-sec-0150"> <h5 class="title">Sensitivity analyses</h5> <p>We planned to use the fixed‐effect model a priori to assess effect sizes. We present a comparison of fixed‐ versus random‐effects in <a href="#CD012621-tbl-0009">Table 2</a>. Where effect sizes differed, this was explained by high heterogeneity between trials. </p> <div class="table" id="CD012621-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: fixed‐effect versus random‐effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Meta‐analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fixed‐effect size and CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random‐effect size and CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.59 (3.95 to 18.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.53 (3.90 to 18.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.17 (40.30 to 56.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.98 (40.74 to 65.23)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.07 to 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.08 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.33 (−8.12 to −4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−8.94 (−13.73 to −4.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.52 (−2.79 to −0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.52 (−2.79 to −0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.16 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.08 to 0.61)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.74 (−6.13 to −3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.02 (−7.02 to −3.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−11.62 (−25.18 to 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−11.62 (−25.18 to 1.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dypnoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.72 (−0.99 to −0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.61 (−1.19 to −0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening requiring intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.27 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.25 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus placebo to on combination therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.66 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.41 to 2.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.66 (9.22 to 30.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.94 (0.23 to 37.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.07 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.04 to 3.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.58 (−6.14 to −3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.12 (−8.21 to −2.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac output</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.53 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.53 to 1.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48 (−0.72 to −0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.36 (−0.84 to 0.12)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.18 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.18 to 0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus ERA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.55 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.55 to 1.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.38 (3.65 to 95.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.38 (3.65 to 95.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.74 to 13.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.74 to 13.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.00 (9.00 to 35.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.00 (9.00 to 35.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.00 (−4.82 to 18.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.00 (−4.82 to 18.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (−2.14 to 6.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (−2.14 to 6.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.49 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.49 to 0.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−1.93 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−1.93 to 1.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.30 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.30 to 0.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 2 Pulmonary hypertension due to left‐heart disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.32 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.20 to 2.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.31 (22.75 to 45.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.44 (‐1.82 to 58.69)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.03 to 0.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.17 (−11.99 to −8.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.58 (−22.28 to 9.12)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (−0.17 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (−0.22 to 0.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TPG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−14.60 (−15.63 to −13.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−14.60 (−15.63 to −13.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.00 (−3.77 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.00 (−3.77 to 1.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27.60 (−30.37 to −24.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27.60 (−30.37 to −24.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dypnoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.51 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.51 to 1.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening requiring intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.66 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.22 to 3.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 3 Pulmonary hypertension due to lung disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.33 (4.78 to 410.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.33 (4.78 to 410.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.04 (7.05 to 21.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.70 (2.00 to 51.39)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−6.65 to 6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−6.65 to 6.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.14 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.14 to 0.74)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.31 (−3.67 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.31 (−3.67 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (−2.76 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (−2.76 to 3.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (−0.07 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (−0.07 to 0.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 4 Pulmonary hypertension due to CTEPH</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.18 (0.78 to 380.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.18 (0.78 to 380.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.73 (−12.72 to 50.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.73 (−12.72 to 50.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.06 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.06 to 0.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.79 (−5.55 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.67 (−6.48 to 3.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (−0.19 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (−0.19 to 0.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (−0.32 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.12 (−0.50 to 0.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 (−3.42 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 (−3.42 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.26 (−1.17 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.26 (−1.17 to 0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mixed pulmonary hypertension group 2 to 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.33 (4.91 to 26.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.33 (4.91 to 26.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.97 (44.88 to 57.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.97 (44.88 to 57.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.00 (−11.92 to −8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.00 (−11.92 to −8.08)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>statistically high heterogeneity </p> <p>CI ‐ confidence interval; CTEPH ‐ chronic thromboembolic pulmonary hypertension; OR ‐ odds ratio; MD ‐ mean difference; PAP ‐ pulmonary artery pressure; PASP ‐ pulmonary artery systemic pressure; PDE5i ‐ phosphodiesterase‐5 inhibitor; PVR ‐ pulmonary vascular resistance; RAP ‐ right atrial pressure; SMD ‐ standardised mean difference; TPG ‐ transpulmonary gradient; WHO ‐ World Health Organization </p> </div> </div> </section> </section> <section id="CD012621-sec-0151"> <h4 class="title">Group 5: Haematological disorders</h4> <p><a href="./references#CD012621-bbs2-0018" title="JalalianR , MoghadamniaAA , TamaddoniA , KhafriS , IranianM . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassaemia intermedia. Heart Lung and Circulation2016;14(26):677–83. JalalianR , TammadoniA , IranianM , SaraviM , MohgadamniaA , KhafiSE . Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta‐thalassemia intermedia. European Heart Journal2015;36:502. ">Jalalian 2015</a> included 44 participants with beta‐thalassaemia intermedia and pulmonary hypertension on transthoracic echocardiogram, and were treated for six weeks with tadalafil (40 mg daily) or placebo. The authors reported a significant improvement in the PASP (post‐treatment tadalafil MD 34.26 mmHg; SE 1.15, compared to post‐treatment placebo MD 44.57 mmHg; SE 0.56; P &lt; 0.001). In the tadalafil group two participants dropped out due to severe headache and one due to severe oedema. Three other participants experienced a mild headache with initiation of tadalafil, which resolved after one week. No deaths occurred after six weeks of this trial. </p> <p><a href="./references#CD012621-bbs2-0021" title="GladwinM , MachadoR , HassellK , YovetichN , GordeukV , GibbsS , et al. Treatment of pulmonary hypertension (PH) and sickle cell disease (scd) with sildenafil (sild) therapy (walk‐phasst): interim report. European Respiratory Society 19th Annual Congress; 2009 September 12‐15; Vienna, Austria. 2009; Vol. 171. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the walk‐PHaSST trial. American Thoracic Society International Conference; 2010 May 14‐19; New Orleans (LA). 2010:A2514. MachadoRF , BarstRJ , YovetichNA , HassellKL , GoldsmithJC , WoolsonR , et al. Safety and efficacy of sildenafil therapy for doppler‐defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk‐PHaSST clinical trial. Blood2009;114(22):Abstract no: 571. YovetichNA , HassellKL , MachadoRF , BarstRJ , GladwinMT . Treatment of pulmonary hypertension and sickle cell disease with sildenafil therapy (walk‐PHaSST): Background, rationale, study design, current enrollment and baseline data. American Journal of Hematology Conference: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting; 2009 Feb 15‐20; Fort Lauderdale (FL). 2009:E197‐8. ">Machado 2009</a> included those with pulmonary hypertension secondary to sickle cell disease and tested sildenafil versus placebo. The study was prematurely stopped due to a statistically significant increase in serious adverse events requiring hospitalisation in the sildenafil arm. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012621-sec-0152" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012621-sec-0152">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012621-sec-0210">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012621-sec-0152"></div> <section id="CD012621-sec-0153"> <h3 class="title" id="CD012621-sec-0153">Summary of main results</h3> <p>This review demonstrates clear statistical and clinical benefit for the use of PDE5 inhibitors in group 1 PAH compared to placebo, in terms of mortality, improvement in WHO functional class, time to clinical worsening, haemodynamics, six‐minute walk distance (6MWD), and quality of life including dyspnoea. Clinicians and patients should be aware of side effects, especially headache, flushing, GI upset, and muscle and joint pain. </p> <p>Three formulations of PDE5 inhibitors were used: sildenafil, tadalafil and vardenafil. Although none of these were compared head‐to‐head, a beneficial direction of effect appeared across all three drugs. Although the magnitude of effect appeared greater in sildenafil compared with tadalafil or vardenafil, this could be due to more studies and participant numbers in the sildenafil arm. In terms of adverse events, there appeared to be a higher chance of headache, GI upset and muscle aches and pains in the tadalafil arm compared to the sildenafil arm. </p> <p>We demonstrate mixed evidence for the use of PDE5 inhibitors for left‐heart disease. The trials included were heterogenous in left‐heart disease secondary to different mechanisms. Overall, there was a statistically and clinically significant improvement across all trials in terms of WHO functional class and 6MWD, and an improvement in haemodynamics, quality of life, and dyspnoea, but this did not confer a clear benefit for mortality. It is unclear if this is due to underpowered studies. In addition, there was some evidence of heart failure exacerbations in one study which included participants with valvular heart disease, but despite this being a known potential side effect of these drugs, few studies reported any adverse events. </p> <p>There is no clear benefit from the use of PDE5 inhibitors in pulmonary hypertension secondary to lung disease, according to this meta‐analysis. There was a statistically but not clinically significant difference in 6MWD, but no benefit for mortality, haemodynamics, quality of life, and clinical worsening. Most studies included COPD patients with pulmonary hypertension; only one included IPF patients. There are no data on PDE5 inhibitors in other lung disease patients. </p> <p>There was no significant benefit for the use of PDE5 inhibitors in CTEPH, when compared to placebo or bosentan, for mortality, clinical worsening, 6MWD, and haemodynamics, but the numbers of participants were small. </p> <p>There may be an improvement in cardiopulmonary haemodynamics with the use of PDE5 inhibitors in pulmonary hypertension due to beta‐thalassaemia intermedia. There may be evidence of harm from the use of PDE5 inhibitors in people with pulmonary hypertension secondary to sickle cell disease. </p> </section> <section id="CD012621-sec-0154"> <h3 class="title" id="CD012621-sec-0154">Overall completeness and applicability of evidence</h3> <p>There are sufficient trials of high quality in the use of PDE5 inhibitors compared to placebo for group 1 PAH. Most trials had a low risk of bias, and the direction of effect was consistent across studies. PDE5 inhibitors are one of five classes of drugs now available for group 1 PAH. Current European Society of Cardiology (ESC) guidelines stratify patients according to levels of risk, which correlate with expected survival (<a href="./references#CD012621-bbs2-0111" title="BouclyA , WeatheraldJ , SavaleL , JaïsX , CottinV , PrevotG , et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal2017;50(2):1700889. ">Boucly 2017</a>; <a href="./references#CD012621-bbs2-0129" title="HoeperMM , KramerT , PanZ , EichstaedtCA , SpiesshoeferJ , BenjaminN , et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal2017;50(2):1700740. ">Hoeper 2017</a>; <a href="./references#CD012621-bbs2-0132" title="KylhammarD , KjellströmB , HjalmarssonC , JanssonK , NisellM , SöderbergS , et al. A comprehensive risk stratification at early follow‐up determines prognosis in pulmonary arterial hypertension. European Heart Journal2018; Vol. 39, issue 47:4175‐81. [DOI: 10.1093/eurheartj/ehx257] ">Kylhammar 2018</a>). The guidelines suggest the use of monotherapy with either a PDE5 inhibitor or an endothelin receptor antagonist (ERA) for people at low risk, and the use of combination therapy or intravenous prostacyclin for those at high risk. Two studies compared the use of PDE5 inhibitors with ERAs, and found a possible benefit for ERA in terms of 6MWD and quality of life, and a non‐statistically significant benefit for improvement in WHO functional class, and clinical worsening, favouring ERAs. </p> <p>The use of step‐up or upfront combination therapy in people at intermediate risk has been suggested by several recent studies, including <a href="./references#CD012621-bbs2-0140" title="PulidoT , AdzerikhoI , ChannickR , DelcroixM , GalièN , GhofraniH , et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine2013;369(9):809‐18. ">SERAPHIN 2013</a> (where macitentan was added to a PDE5 inhibitor or non‐parenteral prostacyclin, and demonstrated delay in clinical worsening), <a href="./references#CD012621-bbs2-0112" title="McLaughlinV , ChannickRN , GhofraniHA , LemariéJC , NaeijeR , PackerM , et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal2014;46(2):405‐13. ">COMPASS‐2 2014</a> (where bosentan was added to sildenafil, and demonstrated a small but statistically significant improvement in 6MWD (22 m), but no change in morbidity or mortality), PACES (<a href="./references#CD012621-bbs2-0030" title="SimonneauG , BurgessG , CollingsL , BarstRJ , GalièN , RubinLJ , et al. Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH). American Thoracic Society International Conference; 2006 May 19‐21; San Diego. 2006:A58. SimonneauG , RubinLJ , GalièN , BarstRJ , FlemingTR , FrostAE . Addition of sildenafil to long‐term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Annals of Internal Medicine2008;149(8):521‐30. ">Simonneau 2008</a>) (where sildenafil was added to epoprostenol and demonstrated a delay in clinical worsening), and <a href="./references#CD012621-bbs2-0123" title="SitbonO , ChannickR , ChinKM , FreyA , GaineS , GalièN , et al. Selexipag for the treatment of pulmonary arterial hypertension. New England Journal of Medicine2015;373(26):2522‐33. ">GRIPHON 2015</a> (where the addition of selexipag to monotherapy demonstrated a delay in clinical worsening). The <a href="./references#CD012621-bbs2-0107" title="GalièN , BarberàJA , FrostAE , GhofraniHA , HoeperMM , McLaughlinVV , et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine2015;373(9):834‐44. ">AMBITION 2015</a> study (included in this review) examined upfront combination therapy and demonstrated a reduction in clinical failure, and an improvement in 6MWD. </p> <p>Pulmonary hypertension secondary to left‐heart disease (PH‐LHD) is by far the most common cause of pulmonary hypertension, and the presence of PH‐LHD leads to worse survival (<a href="./references#CD012621-bbs2-0143" title="StrangeG , PlayfordD , StewartS , DeagueJ , NelsonH , GabbayE . Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart2012;98(4):1805‐11. ">Strange 2012</a>). Studies including participants with PH‐LHD were mixed; when we pooled the studies there was a benefit for exercise parameters and quality of life, but an increased risk of heart failure exacerbations. Previous studies (<a href="./references#CD012621-bbs2-0130" title="JiangG , LiB , ZhangG , XuE , LiuY , XuZ . Effects of sildenafil on prognosis inpatients with pulmonary hypertension after left‐sided valvular surgery. Heart Lung Circulation2014;23:680–5. ">Jiang 2014</a>; <a href="./references#CD012621-bbs2-0133" title="LindmanBR , ZajariasA , MadrazoJA , ShahJ , GageBF , NovakE , et al. Effects of phosphodiesterase type5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation2012;125:2353–62. ">Lindman 2012</a>) have demonstrated acute haemodynamic benefit in these participants, but the long‐term effect remains controversial. <a href="./references#CD012621-bbs2-0003" title="BermejoJ , YottiR , Garcio‐OrtaR , Sanchez‐FernandezP , CastanoM , Segovia‐CuberoJ , et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double‐blind, randomized clinical trial. European Heart Journal2018;39(15):1255‐64. ">Bermejo 2017</a> suggested an initial benefit in 6MWD at three months (although not statistically significant), but this effect disappeared at six months, with no difference in effect between the two arms. In contrast, the other long‐term study (<a href="./references#CD012621-bbs2-0014" title="GuazziM , VicenziM , ArenaR , GuazziM . Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase‐5 inhibition in a 1‐year study. Circulation2011;124(2):164‐74. ">Guazzi 2011a</a> (12 months)) demonstrated a continued, persistent benefit in haemodynamics over time. This suggests that the controversy may lie in the heterogeneity of the cause of left‐heart disease leading to pulmonary hypertension. </p> <p>The evidence for pulmonary hypertension secondary to lung disease was limited to people with COPD. Although there was one small study (an a priori planned substudy of a larger trial) in people with IPF, it is difficult to extrapolate the evidence presented in this meta‐analysis beyond the COPD population. Theoretically, worsening ventilation‐perfusion mismatch induced by pulmonary vasodilators may lead to more pronounced dyspnoea and clinical worsening (<a href="./references#CD012621-bbs2-0142" title="SmithJS , GorbettD , MuellerJ , PerezR , DanielsCJ . Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. American Journal of Medical Science2013;346(3):221‐5. ">Smith 2013</a>), but included studies did not assess dyspnoea, and limited data were provided on clinical worsening. Further trials should include these outcomes. </p> <p>Appropriate and accurate outcome assessment did not occur in all studies. In trials with PH‐LHD, although most participants were initially diagnosed using right‐heart catheterisation, outcome assessment was performed with noninvasive measures such as PASP on transthoracic echocardiogram (TTE). Previous studies (<a href="./references#CD012621-bbs2-0115" title="FarberHW , ForemanAJ , MillerDP , McGoonMD . REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congestive Heart Failure2011;17(2):56‐64. ">Farber 2011</a>) have demonstrated that these noninvasive techniques do not always correlate with invasive haemodynamics, especially in those with left‐heart disease. In addition, the presence of pulmonary hypertension in left‐heart disease has been shown to reduce exercise tolerance and increase hospitalisations for heart failure (<a href="./references#CD012621-bbs2-0145" title="VachiéryJ‐L , AdirY , BarberàJA , ChampionH , CoghlanJG , CottinV , et al. Pulmonary hypertension due to left heart diseases. Journal of the American College of Cardiology2013;62(25 Suppl):D100‐8. ">Vachiéry 2013</a>). However, despite this, only three of five studies reported exercise tolerance, and only two of five reported heart failure exacerbations. Any further studies in PH‐LHD should include 6MWD, invasive haemodynamic data, clinical worsening including heart failure exacerbations, and be adequately powered to detect a difference in these outcomes. </p> </section> <section id="CD012621-sec-0155"> <h3 class="title" id="CD012621-sec-0155">Quality of the evidence</h3> <p>For trials including group 1 PAH participants comparing PDE5 inhibitors to placebo, the quality of evidence was high across all outcomes except for six‐minute walk distance, and cardiac index, which were downgraded to moderate due to high heterogeneity, although the effect was consistent across trials. For PAH trials comparing PDE5 inhibitors to placebo whilst on additional therapy and trials comparing PDE5 inhibitors to ERAs, the quality of the evidence was reduced due to smaller participant numbers. Follow‐up was as long as 12 months, but the average follow‐up was only 14 weeks. Open‐label extension or real world registry data may be useful for longer‐term effects. </p> <p>Although there were five studies examining PH‐LHD, the numbers in each study were small, and studies were significantly heterogeneous. <a href="./references#CD012621-bbs2-0024" title="Artem OvchinnikovAG , PotekhinaAV , GavryushinaSV , AgeevFT . Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre‐and post‐capillary pulmonary hypertension. European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria. 2018; Vol. 20 (Supplement 1):567‐8. OvchinnikovAG , GavryushinaSV , MasenkoVP , AgeevFT . Phosphodiesterase‐5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension. European Journal of Heart Failure2015;17(Suppl. 1):5–441. ">Ovchinnov 2015</a> was a poor‐quality study, where randomisation and allocation concealment were not reported, dropouts and cross‐overs were not reported, and only quantitative data from the intervention arm was reported. </p> </section> <section id="CD012621-sec-0156"> <h3 class="title" id="CD012621-sec-0156">Potential biases in the review process</h3> <p>We conducted this review in accordance with established Cochrane standards. Two review authors independently screened search results and resolved discrepancies by discussion and consensus. We did not restrict the literature search by language. Publication bias is possible, whereby failure to identify unpublished negative trials could have led to an overestimation of effect. </p> </section> <section id="CD012621-sec-0157"> <h3 class="title" id="CD012621-sec-0157">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are consistent with the current ESC/ERS guidelines (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>), which recommend the use of PDE5 inhibitors for monotherapy as level IA/B evidence for WHO functional class I ‐ III patients, and as level IIb evidence for WHO functional class IV patients (as there is stronger evidence of effect for combination therapy and intravenous prostacyclins). Similarly, the current ESC/ERS guidelines do not recommend the use of PDE5 inhibitors for left‐heart disease‐ or lung disease‐related pulmonary hypertension. Where PDE5 inhibitors are used as part of combination therapy, caution should be used in adding these to riociguat, due to potentially unfavourable side effects and lack of additional clinical benefit (<a href="./references#CD012621-bbs2-0117" title="GalièN , MüllerK , ScaliseAV , GrünigE . PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. European Respiratory Journal2015;45(5):1314‐22. ">Galiè 2015b</a>). </p> <p>No trials have compared individual PDE5 inhibitors head‐to‐head, and given the overall class benefit it is unlikely that these studies will be conducted. Our data suggest that there may be a better treatment effect with sildenafil compared to tadalafil, but this may be influenced by the greater number of studies conducted using sildenafil compared to tadalafil. The choice of agent is likely to be nuanced and influenced by the individual patient profile with respect to side effects. The SITAR study (<a href="./references#CD012621-bbs2-0116" title="FrantzR , DurstL , BurgerC , OudizR , BourgeR , FrancoV . Conversion From sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) Study. Journal of Cardiovascular Pharmacology and Therapeutics2014;19(6):550‐7. ">Frantz 2014</a>) rotated participants from sildenafil to tadalafil, and found an initial increase in side effects including headache and gastrointestinal upset, but this improved over time. </p> <p>Our data demonstrating no clear benefit for the use of PDE5 inhibitors in those with lung disease‐associated pulmonary hypertension is consistent with the ESC guidelines (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>) and with other published data using PH‐specific therapy in people with interstitial lung disease (ILD). <a href="./references#CD012621-bbs2-0015" title="HanMK , BachDS , HaganPG , YowE , FlahertyKR , ToewsGB . Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right‐sided ventricular dysfunction. Chest2013;143(6):1699‐708. ">Han 2013</a> (pulmonary hypertension associated with lung disease) was a prespecified substudy of the STEP‐IPF trial (<a href="./references#CD012621-bbs2-0146" title="ZismanDA , SchwarzM , AnstromKJ , CollardHR , FlahertyKR , HunninghakeGW , et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. New England Journal of Medicine2010;363(7):620‐8. ">Zisman 2010</a>), which included people with idiopathic pulmonary fibrosis (IPF), and found no benefit in terms of 6MWD, exacerbations or mortality. </p> <p>Interestingly, there appeared to be no significant benefit for the use of PDE5 inhibitors in people with CTEPH. Current ESC/ERS guidelines (<a href="./references#CD012621-bbs2-0118" title="GalièN , HumbertM , VachieryJL , GibbsS , LangI , TorbickiA , et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Revista Espanola de Cardiologia2016;69(2):177. ">Galiè 2016b</a>) recommend surgical pulmonary endarterectomy as first line treatment based on long term international registry data which demonstrates a mortality benefit (<a href="./references#CD012621-bbs2-0114" title="DelcroixM , LangI , Pepke‐ZabaJ , JansaP , D'ArminiA , SnijderR . Long‐term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation2016;133(9):859–71. ">Delcroix 2016</a>), and the use of riociguat medical therapy in those who are non‐operable candidates (<a href="./references#CD012621-bbs2-0120" title="GhofraniHA , D'ArminiAM , GrimmingerF , HoeperMM , JansaP , Kim NHN . Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. New England Journal of Medicine2013;369(4):319‐29. ">Ghofrani 2013</a>). Therefore, these treatments could be considered in preference to PDE5 inhibitors. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012621-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012621-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012621-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.1 Improvement in WHO functional class." data-id="CD012621-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.3 Mortality." data-id="CD012621-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, outcome: 1.3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Cates Plot for mortality with PDE5 inhibitor treatment in Group 1 PAH" data-id="CD012621-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Cates Plot for mortality with PDE5 inhibitor treatment in Group 1 PAH</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), outcome: 4.2 Six‐minute walk distance." data-id="CD012621-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), outcome: 4.2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Group 3 Pulmonary Hypertension due to lung disease, outcome: 5.2 Six‐minute walk distance." data-id="CD012621-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Group 3 Pulmonary Hypertension due to lung disease, outcome: 5.2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 Group 4 Pulmonary Hypertension due to CTEPH, outcome: 6.2 Six‐minute walk distance." data-id="CD012621-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 Group 4 Pulmonary Hypertension due to CTEPH, outcome: 6.2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 3 Mortality." data-id="CD012621-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 4 PAP." data-id="CD012621-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 4 PAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 5 RAP." data-id="CD012621-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 5 RAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 6 CI." data-id="CD012621-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 6 CI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 7 PVR." data-id="CD012621-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 7 PVR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 8 PASP." data-id="CD012621-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 8 PASP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 9 Dyspnoea." data-id="CD012621-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 9 Dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 10 Clinical worsening requiring intervention." data-id="CD012621-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 10 Clinical worsening requiring intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 11 Adverse events." data-id="CD012621-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, Outcome 11 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 1 Improvement in WHO functional Class." data-id="CD012621-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 1 Improvement in WHO functional Class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 3 Mortality." data-id="CD012621-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 4 PAP." data-id="CD012621-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 4 PAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 5 Cardiac Output." data-id="CD012621-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 5 Cardiac Output. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 6 PVR." data-id="CD012621-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 6 PVR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 7 Clinical worsening." data-id="CD012621-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 7 Clinical worsening. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 8 Adverse events." data-id="CD012621-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy, Outcome 8 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 3 Mortality." data-id="CD012621-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 4 PAP." data-id="CD012621-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 4 PAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 5 RAP." data-id="CD012621-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 5 RAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 6 CI." data-id="CD012621-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 6 CI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 7 PVR." data-id="CD012621-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 7 PVR. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 8 Quality of life." data-id="CD012621-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 8 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 9 Clinical worsening requiring hospitalisation." data-id="CD012621-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 9 Clinical worsening requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 10 Adverse events." data-id="CD012621-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA, Outcome 10 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 3 Mortality." data-id="CD012621-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 3 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 4 mean PAP." data-id="CD012621-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 4 mean PAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 5 Cardiac Index." data-id="CD012621-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 5 Cardiac Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 6 TPG." data-id="CD012621-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 6 TPG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 7 RAP." data-id="CD012621-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 7 RAP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 8 PASP." data-id="CD012621-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 8 PASP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 9 Dyspnoea." data-id="CD012621-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 9 Dyspnoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 10 Clinical worsening." data-id="CD012621-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo), Outcome 10 Clinical worsening. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 3 QOL." data-id="CD012621-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 3 QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 4 mean PAP." data-id="CD012621-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 4 mean PAP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 5 Cardiac Index." data-id="CD012621-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 5 Cardiac Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 6 PVR." data-id="CD012621-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 6 PVR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 7 RAP." data-id="CD012621-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Group 3 Pulmonary Hypertension due to lung disease, Outcome 7 RAP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 2 Six‐minute walk distance." data-id="CD012621-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 2 Six‐minute walk distance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 3 Mortality." data-id="CD012621-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 3 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 4 mean PAP." data-id="CD012621-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 4 mean PAP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 5 Cardiac Index." data-id="CD012621-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 5 Cardiac Index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 6 PVR." data-id="CD012621-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 6 PVR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 7 RAP." data-id="CD012621-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 7 RAP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 8 QOL." data-id="CD012621-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 8 QOL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 9 Adverse events." data-id="CD012621-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Group 4 Pulmonary Hypertension due to CTEPH, Outcome 9 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 1 Improvement in WHO functional class." data-id="CD012621-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 1 Improvement in WHO functional class. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 2 6MWD." data-id="CD012621-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 2 6MWD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012621-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/urn:x-wiley:14651858:media:CD012621:CD012621-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_t/tCD012621-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 3 PASP." data-id="CD012621-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Mixed Pulmonary Hypertension group 2‐4, Outcome 3 PASP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/media/CDSR/CD012621/image_n/nCD012621-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>61 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000<br/> (204 to 549) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 8.59<br/> (3.95 to 18.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 170 ‐ 319 m<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 48 metres higher<br/> (40 higher to 56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>880<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (3 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.22<br/> (0.07 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1119<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>SF‐36: (scores 1 to 100, higher scores indicate better QoL)</p> <p>EQ‐5D questionnaire: (higher scores indicate worse QoL)</p> <p>CHFQ: (lower scores indicate worse QoL)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a> found a statistically significant improvement in all SF‐36 domains for sildenafil‐treated participants, and when compared to placebo in physical functioning (P &lt; 0.001), general health (P &lt; 0.001), and vitality (P &lt; 0.05). There was also a statistically significant improvement in placebo‐treated participants in the physical functioning domain. </p> <p><a href="./references#CD012621-bbs2-0009" title="GalièN , GhofraniHA , TorbickiA , BarstRJ , RubinLJ , BadeschD , et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine2005;353(20):2148‐57. PeacockA , BurgessG , ParpiaT , BarstRJ . Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients. European Respiratory Society 15th Annual Congress; 2005 Sep 17‐20; Copenhagen, Denmark. 2005:Abstract No. 3127. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Effects of tadalafil on health‐related quality of life in patients with pulmonary arterial hypertension. European Heart Journal2009;30(suppl 1):442. Pepke‐ZabaJ , BeardsworthA , ChanM , AngalakuditiM . Tadalafil therapy and health‐related quality of life in pulmonary arterial hypertension. Current Medical Research and Opinion2009;25(10):2479‐85. Pepke‐ZabaJ , BrownM , ParpiaT , GilbertC , BurgessG . Sildenafil improves health‐related quality of life in pulmonary arterial hypertension (PAH) patients. European Respiratory Society Annual Congress. 2005 September 17‐20; Copenhagen, Denmark. 2005; Vol. 26:Abstract No. 848. Pepke‐ZabaJ , BrownMCJ , ParpiaT , GilbertC , BurgessG . The impact of sildenafil citrate on health‐related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double‐blind, placebo controlled trial. American Thoracic Society International Conference; 2005 May 20‐25; San Diego (CA). 2005:B16. ">Galiè 2005a</a> found statistically significant improvements for the EQ‐5D current health status (P &lt; 0.01) and utility index (P &lt; 0.01).<br/> <a href="./references#CD012621-bbs2-0029" title="SastryBK , NarasimhanC , ReddyNK , RajuBS . Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo‐controlled, double‐blind, crossover study. Journal of the American College of Cardiology2004;43(7):1149‐53. ">Sastry 2004</a> found a statistically significant difference for the CHFQ fatigue domain (sildenafil post‐treatment score 22.33, SD 4.82 compared to placebo post‐treatment score 20.67, SD 5.19; P = 0.04), and a non‐statistically significant difference in the emotional function domain (sildenafil post‐treatment score 37.33, SD 9.3, compared to placebo post‐treatment score 34.71, SD 10.91; P = 0.06), favouring sildenafil compared with placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data considered too heterogeneous to meta‐analyse</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.43 mmHg lower (8.13 lower to 4.74 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/> (6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.35 mmHg lower (2.34 lower to 0.36 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.28L/min/m<sup>2</sup> higher (0.16 higher to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<sup>b</sup><br/> MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.74 WU lower (6.13 lower to 3.35 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>266<br/> (3 RCTs)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR. the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>EQ‐5D</b> : EuroQoL 5D; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PH</b> : pulmonary hypertension; <b>PVR</b> : pulmonary vascular resistance; <b>RAP</b> : right atrial pressure; <b>RCT</b> : randomised controlled trials; <b>SD</b> : standard deviation; <b>SF‐36</b> : Medical Outcomes Study 36‐item short form; <b>WU</b> : woods units; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Post‐treatment values for participants in the placebo group were presented in two studies only; the remaining included studies presented a mean difference only.<br/> <sup>b</sup>Downgraded due to imprecision owing to significantly high heterogeneity, although the direction of effect is consistent. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors plus other disease‐modifying therapies<br/> <b>Comparison:</b> placebo plus other disease‐modifying therapies </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo, on combination therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (191 to 437) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20<br/> (0.66 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 341 ‐ 377 m<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 metres higher<br/> (9 higher to 30 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>509<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (2 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.26<br/> (0.07 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>492<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>physical functioning on SF‐36 (higher scores indicate better quality of life)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0.3 (4.7 higher to 4.1 higher)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.8 (3.6 higher to 12.1 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.58 mmHg lower<br/> (6.14 lower to 3.01 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac output</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.87 L/min higher<br/> (0.53 higher to 1.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>310<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac output, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.48 lower<br/> (0.72 lower to 0.25 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RCT</b> : randomised controlled trials; <b>SMD</b> : standardised mean difference; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision owing to small participant numbers and inconsistent direction of effect.<br/> <sup>b</sup>Range of baseline values, as studies only presented mean difference values for analysis.<br/> <sup>c</sup>Downgraded due to imprecision as the confidence interval crosses the line of no difference.<br/> <sup>d</sup>Downgraded due to imprecision owing to small participant numbers in one trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to placebo, on combination therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to ERA</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 1 Pulmonary Arterial Hypertension ‐ PDE5i compared to ERA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary arterial hypertension<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> endothelin receptor antagonists<b>(</b>ERA) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ERA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>325 per 1000<br/> (220 to 450) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.94<br/> (0.55 to 1.60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 290 ‐ 354 m<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 49 higher<br/> (4 higher to 95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6MWD in PAH MCID is 41 metres</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (11 to 167) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.19<br/> (0.74 to 13.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> <p>Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 22 higher<br/> (9 higher to 35 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 7.00 mmHg lower (4.82 lower to 18.82 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2 mmHg higher (2.14 lower to 6.14 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 L/min/m<sup>2</sup> higher (0.49 lower to 0.49 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 WU lower (1.93 lower to 1.93 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR. the worse the PH</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to imprecision.<br/> <sup>b</sup>Range of baseline values, as studies only presented mean difference values for analysis.<br/> <sup>c</sup>Downgraded twice due to imprecision and small participant numbers.<br/> <sup>d</sup>Downgraded twice due to very small participant numbers and high risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Group 1 Pulmonary arterial hypertension ‐ PDE5i compared to ERA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 2 Pulmonary hypertension due to left‐heart disease ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to left‐heart disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>403 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>263 per 1000<br/> (178 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.53<br/> (0.32 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 34 metres higher<br/> (23 higher to 46 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000 (6 to 114)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.27 (0.28 to 5.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19.83 points higher (8.23 higher to 31.44 higher)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12.05 points higher (1.14 higher to 22.96 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kansas City Cardiomyopathy Questionnaire (higher scores reflect better health status)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10.17 mmHg lower<br/> (11.99 lower to 8.35 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.07 L/min/m<sup>2</sup> higher<br/> (0.17 lower to 0.3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>6MWD:</b> six‐minute walk distance; <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to high heterogeneity and inconsistent direction of effect.<br/> <sup>b</sup>Downgraded due to imprecision as the confidence interval crosses the line of no difference.<br/> <sup>c</sup>Downgraded twice due to imprecision owing to few participant numbers in one trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 3 Pulmonary hypertension due to lung disease ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to lung disease<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>700 per 1000<br/> (201 to 956) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 44.33<br/> (4.78 to 410.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 237 ‐ 297 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 27 metres higher<br/> (2 higher to 51 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>350<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.19 higher<br/> (0.07 lower to 0.44 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐36 overall quality of life (higher scores indicate better quality of life)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.14 mmHg lower<br/> (6.65 lower to 6.37 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the mean PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.3 L/min/m<sup>2</sup> higher<br/> (0.14 lower to 0.74 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.31 WU lower<br/> (3.67 lower to 1.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RAP</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.36 mmHg higher<br/> (2.76 lower to 3.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the RAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MCID:</b> minimal clinically important difference; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RAP</b> : right atrial pressure; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision owing to small participant numbers.<br/> <sup>b</sup>Downgraded once due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Group 4 Pulmonary hypertension due to CTEPH ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension due to CTEPH<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with comparison (placebo/sildenafil)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>444 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 17.18<br/> (0.78 to 380.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance ‐ sildenafil compared to placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Baseline 331 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 18 metres higher<br/> (24 lower to 59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance ‐ sildenafil compared to bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Ranges from 422 ‐ 455 metres</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 20 metres higher<br/> (28 lower to 69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (9 to 261) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.36 (0.22 to 8.48)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.26 lower<br/> (1.17 lower to 0.64 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CamPHOR scale; higher scores indicate worse quality of life</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 6.2 mmHg lower<br/> (12.4 lower to 0 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PAP ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.76 mmHg higher<br/> (3.96 lower to 5.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PAP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0 L/min/m<sup>2</sup> higher<br/> (0.4 lower to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac index ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.04 L/min/m<sup>2</sup> higher<br/> (0.22 lower to 0.31 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The lower the cardiac index, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR ‐ sildenafil versus placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.89 WU lower<br/> (1.85 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PVR ‐ sildenafil versus bosentan</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 WU lower<br/> (0.27 lower to 0.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PVR, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>CTEPH:</b> chronic thromboembolic pulmonary hypertension; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PAP</b> : pulmonary arterial pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>PVR</b> : pulmonary vascular resistance; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision owing to small participant numbers in only one trial.<br/> <sup>b</sup>Downgraded once due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012621-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i compared to placebo</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mixed pulmonary hypertension group 2 ‐ 4 ‐</b> PDE5i compared to placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with pulmonary hypertension group 2 ‐ 4<br/> <b>Setting:</b> outpatients<br/> <b>Intervention:</b> PDE5 inhibitors<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with PDE5i</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Improvement in WHO functional class</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 11.31<br/> (4.90 to 26.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1000<br/> (438 to 806) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Six‐minute walk distance</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No data provided</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 51 metres higher<br/> (7 higher to 95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PASP</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 10 mmHg lower<br/> (11.92 lower to 8.08 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The higher the PASP, the worse the pulmonary hypertension</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>MD</b> : mean difference; <b>OR:</b> odds ratio; <b>PASP</b> : pulmonary artery systolic pressure; <b>PDE‐5i:</b> phosphodiesterase‐5 inhibitor; <b>RCT</b> : randomised controlled trials; <b>WHO</b>: World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision owing to small participant numbers.<br/> <sup>b</sup>The information is from studies at low or unclear risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i compared to placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012621-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organisation/World Symposium classification of pulmonary hypertension</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WHO group</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary arterial hypertension</p> <p> <ul id="CD012621-list-0001"> <li> <p>idiopathic PAH</p> </li> <li> <p>PAH with vasoreactivity</p> </li> <li> <p>heritable PAH</p> </li> <li> <p>drugs and toxins</p> </li> <li> <p>associated with:</p> <ul id="CD012621-list-0002"> <li> <p>connective tissue disease;</p> </li> <li> <p>HIV;</p> </li> <li> <p>portal hypertension;</p> </li> <li> <p>congenital heart disease;</p> </li> <li> <p>schistosomiasis.</p> </li> </ul> </li> </ul> </p> <p>Pulmonary veno‐occlusive disease/pulmonary capillary haemangiomatosis</p> <p>Persistent pulmonary hypertension of the newborn</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pumonary hypertension due to left heart disease</p> <p> <ul id="CD012621-list-0003"> <li> <p>due to left heart failure with preserved ejection fraction</p> </li> <li> <p>due to left heart failure with reduced ejection fraction</p> </li> </ul> </p> <p>Valvular heart disease</p> <p>Congenital post‐capillary obstructive lesions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension due to chronic lung disease or chronic hypoxaemia, or both</p> <p> <ul id="CD012621-list-0004"> <li> <p>obstructive lung disease</p> </li> <li> <p>restrictive lung disease</p> </li> <li> <p>other lung diseases with a mixed obstructive/restrictive pattern</p> </li> <li> <p>sleep disordered breathing</p> </li> <li> <p>alveolar hypoventilation disorders</p> </li> <li> <p>chronic exposures to high altitudes</p> </li> <li> <p>developmental lung diseases</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension due to pulmonary artery obstruction</p> <p> <ul id="CD012621-list-0005"> <li> <p>chronic thromboembolic pulmonary hypertension</p> </li> <li> <p>other pulmonary artery obstructions</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary hypertension with unclear mechanisms</p> <p> <ul id="CD012621-list-0006"> <li> <p>haematologic disorders (chronic haemolytic anaemia, myeloproliferative disorders, splenectomy) </p> </li> <li> <p>systemic disorders (sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis) </p> </li> <li> <p>metabolic disorders (glycogen storage disease, Gaucher disease, thyroid disorders)</p> </li> <li> <p>others (pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis, chronic renal failure (with/without dialysis), segmental pulmonary hypertension) </p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>PAH: pulmonary arterial hypertension</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">World Health Organisation/World Symposium classification of pulmonary hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012621-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: fixed‐effect versus random‐effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Meta‐analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect measure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fixed‐effect size and CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Random‐effect size and CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.59 (3.95 to 18.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.53 (3.90 to 18.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.17 (40.30 to 56.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.98 (40.74 to 65.23)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (0.07 to 0.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.08 to 0.95)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.33 (−8.12 to −4.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−8.94 (−13.73 to −4.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.52 (−2.79 to −0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.52 (−2.79 to −0.24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28 (0.16 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 (0.08 to 0.61)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.74 (−6.13 to −3.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.02 (−7.02 to −3.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−11.62 (−25.18 to 1.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−11.62 (−25.18 to 1.94)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dypnoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.72 (−0.99 to −0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.61 (−1.19 to −0.02)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening requiring intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.27 to 1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.25 to 1.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus placebo to on combination therapy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 (0.66 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09 (0.41 to 2.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.66 (9.22 to 30.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.94 (0.23 to 37.65)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 (0.07 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.04 to 3.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4.58 (−6.14 to −3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−5.12 (−8.21 to −2.03)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac output</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.53 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.53 to 1.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.48 (−0.72 to −0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.36 (−0.84 to 0.12)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.18 to 0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 (0.18 to 0.63)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 1 Pulmonary arterial hypertension ‐ PDE5i versus ERA</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.55 to 1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.55 to 1.60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.38 (3.65 to 95.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.38 (3.65 to 95.11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.74 to 13.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.19 (0.74 to 13.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.00 (9.00 to 35.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.00 (9.00 to 35.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.00 (−4.82 to 18.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.00 (−4.82 to 18.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (−2.14 to 6.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.00 (−2.14 to 6.14)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.49 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.49 to 0.49)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−1.93 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−1.93 to 1.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.30 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 (0.30 to 0.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 2 Pulmonary hypertension due to left‐heart disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.32 to 0.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.20 to 2.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.31 (22.75 to 45.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.44 (‐1.82 to 58.69)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.03 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.03 to 0.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.17 (−11.99 to −8.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−6.58 (−22.28 to 9.12)<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07 (−0.17 to 0.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (−0.22 to 0.34)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>TPG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−14.60 (−15.63 to −13.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−14.60 (−15.63 to −13.57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.00 (−3.77 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.00 (−3.77 to 1.77)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27.60 (−30.37 to −24.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−27.60 (−30.37 to −24.83)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dypnoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.51 to 1.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 (0.51 to 1.79)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical worsening requiring intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 (0.66 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 (0.22 to 3.46)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 3 Pulmonary hypertension due to lung disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.33 (4.78 to 410.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.33 (4.78 to 410.93)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.04 (7.05 to 21.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.70 (2.00 to 51.39)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−6.65 to 6.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−6.65 to 6.37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.14 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30 (−0.14 to 0.74)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.31 (−3.67 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.31 (−3.67 to 1.05)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (−2.76 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36 (−2.76 to 3.48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (−0.07 to 0.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19 (−0.07 to 0.44)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Group 4 Pulmonary hypertension due to CTEPH</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.18 (0.78 to 380.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.18 (0.78 to 380.85)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.73 (−12.72 to 50.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.73 (−12.72 to 50.19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.06 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01 (−0.06 to 0.08)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean PAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.79 (−5.55 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−1.67 (−6.48 to 3.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cardiac index</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (−0.19 to 0.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (−0.19 to 0.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PVR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.07 (−0.32 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.12 (−0.50 to 0.25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RAP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 (−3.42 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.98 (−3.42 to 1.47)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.26 (−1.17 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.26 (−1.17 to 0.64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Mixed pulmonary hypertension group 2 to 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Improvement in WHO functional Class</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.33 (4.91 to 26.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.33 (4.91 to 26.15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Six‐minute walk distance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.97 (44.88 to 57.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.97 (44.88 to 57.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PASP</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.00 (−11.92 to −8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−10.00 (−11.92 to −8.08)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>statistically high heterogeneity </p> <p>CI ‐ confidence interval; CTEPH ‐ chronic thromboembolic pulmonary hypertension; OR ‐ odds ratio; MD ‐ mean difference; PAP ‐ pulmonary artery pressure; PASP ‐ pulmonary artery systemic pressure; PDE5i ‐ phosphodiesterase‐5 inhibitor; PVR ‐ pulmonary vascular resistance; RAP ‐ right atrial pressure; SMD ‐ standardised mean difference; TPG ‐ transpulmonary gradient; WHO ‐ World Health Organization </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analysis: fixed‐effect versus random‐effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/full#CD012621-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.59 [3.95, 18.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.24 [3.69, 28.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.71 [1.88, 31.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.66, 47.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>48.17 [40.30, 56.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>56.91 [44.40, 69.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>38.46 [27.60, 49.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>69.0 [41.00, 97.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.07, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.43 [‐8.13, ‐4.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.34 [‐9.35, ‐5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.67 [‐7.55, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.3 [‐10.60, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐2.34, ‐0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.30, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐4.30, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.16, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.28, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.18, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.10, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PVR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.74 [‐6.13, ‐3.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.87 [‐5.67, ‐2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.32 [‐10.42, ‐4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.7 [‐7.80, ‐1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 PASP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.62 [‐25.18, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.0 [‐23.64, 9.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.75 [‐44.14, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐0.99, ‐0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.90, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐1.65, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.70, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical worsening requiring intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.27, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Sildenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.17, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Tadalafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.27, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Vardenafil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.33, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 GI upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.07, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.12 [1.83, 9.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Muscle and joint pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [1.59, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.83, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6 Respiratory symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.89, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7 Visual disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.58, 7.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional Class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.66, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.66 [9.22, 30.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.58 [‐6.14, ‐3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiac Output <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PVR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.21, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.74, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 GI upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.30, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.63, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Muscle and joint pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.28, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Epistaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.34, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Visual disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.95 [0.97, 16.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus placebo, on combination therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>49.38 [3.65, 95.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.74, 13.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [‐4.82, 18.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 RAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐2.14, 6.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.49, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PVR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.93, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical worsening requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.30, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 GI upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Muscle or joint pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Respiratory symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Group 1 Pulmonary Arterial Hypertension ‐ PDE5i versus ERA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.32, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.31 [22.75, 45.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.28, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 mean PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.17 [‐11.99, ‐8.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiac Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.17, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 TPG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 RAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 PASP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Dyspnoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical worsening <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.22, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Group 2 Pulmonary hypertension due to left heart disease (sildenafil v placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Group 3 Pulmonary Hypertension due to lung disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.70 [2.00, 51.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.07, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 mean PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐6.65, 6.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiac Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PVR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 RAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Group 3 Pulmonary Hypertension due to lung disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Group 4 Pulmonary Hypertension due to CTEPH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Six‐minute walk distance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.5 [‐23.90, 58.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.42 [‐27.95, 68.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.22, 8.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 mean PAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.2 [‐12.40, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [‐3.96, 5.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Cardiac Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.40, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.22, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PVR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.85, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.27, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 RAP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Sildenafil versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.9 [‐6.10, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Sildenafil versus bosentan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐3.77, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 GI upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Group 4 Pulmonary Hypertension due to CTEPH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012621-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Mixed Pulmonary Hypertension group 2‐4</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in WHO functional class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.31 [4.90, 26.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 6MWD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PASP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.0 [‐11.92, ‐8.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Mixed Pulmonary Hypertension group 2‐4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012621.pub2/references#CD012621-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012621.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012621-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012621-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012621-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012621-note-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012621-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012621-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012621\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012621\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012621\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012621\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012621\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=UDgTyLGV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012621.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012621.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012621.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012621.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012621.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717417313"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012621.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717417317"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012621.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db764ad829365',t:'MTc0MDcxNzQxNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 